

CURRICULUM VITAE

Mark Andrew Hlatky, M.D.

Office Address:

Stanford University School of Medicine
HRP Redwood Building, Room 150
259 Campus Drive
Stanford, California 94305-5405
(650) 723-6426
email: hlatky@stanford.edu

Education:

Massachusetts Institute of Technology Cambridge, MA (B.S., Physics, 1972; Phi Beta Kappa; Sloan Scholar)	1968-1972
University of Pennsylvania School of Medicine Philadelphia, PA (M.D., 1976)	1972-1976

Post-Doctoral Training:

Intern and Resident in Internal Medicine University of Arizona Tucson, AZ	1976-1979
Robert Wood Johnson Clinical Scholar University of California, San Francisco San Francisco, CA	1979-1981
Cardiology Fellow, Duke University Medical Center Durham, NC	1981-1983

Additional Training:

Genetic Approaches to Complex Heart, Lung and Blood Diseases Course Jackson Laboratories Bar Harbor, ME	2001
---	------

Specialty Certifications:

Internal Medicine	1979
Cardiovascular Disease	1983

Mark Andrew Hlatky, MD/Page 2

Medical Licensure:

California (#G38785) 1979

Academic Appointments:

Associate in Medicine,
Cardiovascular Division,
Duke University Medical Center 1983-1986

Assistant Professor of Medicine,
Cardiovascular Division,
Duke University Medical Center 1986-1989

Associate Professor of Health Research and Policy
Associate Professor of Medicine (Cardiovascular Medicine)
Stanford University School of Medicine 1989-1996

Professor of Health Research and Policy
Professor of Medicine (Cardiovascular Medicine)
Stanford University School of Medicine 1996-Present

Adjunct Investigator, Division of Research,
Kaiser Permanente, Northern California 2007-Present

Administrative Positions:

Associate Director,
Duke Databank for Cardiovascular Disease,
Duke University Medical Center 1983-1989

Chief, Division of Health Services Research
Stanford University School of Medicine 1989-2001

Director, Health Services Research Graduate Degree Program
Stanford University School of Medicine 1989-Present

Chair, Department of Health Research and Policy
Stanford University School of Medicine 1996-2003

Co-Director, UCSF-Stanford Evidence-based Practice Center 1997-2002

Co-Director, Donald W. Reynolds Cardiovascular Clinical Research Center 2000-2001

Director, Donald W. Reynolds Cardiovascular Clinical Research Center 2002-2006

Director, Stanford-Kaiser Cardiovascular Outcomes Research Center 2008-2013

Mark Andrew Hlatky, MD/Page 3

Hospital Appointments:

Duke University Medical Center Cardiac Care Unit (Attending)	1986-1989
Heart Station (Co-Director)	1985-1989
Preventive Approach to Cardiology Program (Attending)	1983-1985
Cardiology Consult Service (Attending)	1983-1989
General Medical Service (Attending)	1983-1989
 Stanford University Medical Center Cardiovascular Medicine Service (Attending)	 1989-Present

Honors and Awards:

Simon Dack Award for Outstanding Scholarship, JACC Journals, American College of Cardiology	2011
Outstanding Lifetime Achievement Award, Council on Quality of Care and Outcomes Research, American Heart Association	2014
Distinguished Scientist Award, American Heart Association	2014
Distinguished Scientist Award, American College of Cardiology	2015

Professional Affiliations:

American College of Cardiology (Fellow)
American Heart Association (Fellow)

Professional Activities:

1. *Scientific Review Committees*

National Institutes of Health Epidemiology and Disease Control II Study Section (Ad-Hoc Member)	1988
NHLBI Special Emphasis Panel to evaluate mentored clinical research applications (Member)	2000
Protocol Review Committee for the Claudication: Exercise vs. Endovascular Revascularization (CLEVER) Trial (Member)	2006
Clinical Trials Review Committee (Ad Hoc Member)	2006
Institutional Clinical Translational Science Award Review Committee	2006

Mark Andrew Hlatky, MD/Page 4

Agency for Health Care Policy and Research Health Care Technology Study Section (Member)	1992-1996
Ad-Hoc Grant Reviewer Agency for Health Care Policy and Research American Heart Association National Science Foundation Robert Wood Johnson Foundation Doris Duke Foundation Swiss National Science Foundation	
2. <i>Editorial Activities</i>	
Associate Editor, Journal of the American College of Cardiology	2008-2019
Associate Editor, Journal of Interventional Cardiac Electrophysiology	2011-2012
<i>Editorial Boards</i>	
Journal of the American College of Cardiology	1995-1997, 2002-2008
American Heart Journal	1996-Present
Cardiac Electrophysiology Review	1996-2003
American Journal of Medicine	1997-Present
Journal of Invasive Cardiology	1997-Present
Circulation	2014-present
3. <i>Advisory Committees</i>	
RAND/Academic Medical Centers Consortium Cardiac Advisory Panel on the Appropriateness of Coronary Artery Bypass Graft Surgery and Percutaneous Transluminal Coronary Angioplasty	1990
Veterans Affairs HSR & D Far West Field Program Center for Health Care Evaluation	1990-Present
State of California Office of Statewide Health Planning and Development California Health Policy and Data Advisory Commission Clinical Advisory Panel on Acute Myocardial Infarction Outcomes AB524 Technical Advisory Committee	1992-1995 1999-2011
Harvard University Center for Risk Analysis National Advisory Committee	1995-1996
Foundation for Accountability Performance Measures in Coronary Disease	1997

Mark Andrew Hlatky, MD/Page 5

RAND Adult Global Quality Assessment Tool Project Cardiopulmonary Health Care Panel	1997
University of California Tobacco-Related Disease Research Program Scientific Advisory Committee (Member) Scientific Advisory Committee (Chair)	1999-2005 2003-2004
Fudan University Center for Evidence-Based Medicine	2004-2006
Blue Cross and Blue Shield Association Technology Evaluation Center Medical Advisory Panel Scientific Advisor	2004-present 2011-present
Washington University Clinical Research Curriculum External Advisory Committee	2006-2007
National Heart, Lung, and Blood Institute Strategic Planning Working Group on Heart Failure and Cardiomyopathy Working Group on Standardization of Lipids, Lipoproteins, and Other Cardiovascular Biomarkers	2006 2007
Centers for Medicare and Medicaid Services Medicare Evidence Development and Coverage Advisory Committee	2006-2009, 2011-2013
Institute of Medicine Committee on Social Security Cardiovascular Disability Criteria	2009-2010
<i>4. Clinical Guidelines Development</i>	
ACC/AHA Committee to Develop Guidelines for the Management of Congestive Heart Failure	1992-1995
ACC/AHA Committee to Revise Guidelines for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices	1996-1997
ACC/AHA/ACP Committee to Develop Guidelines for the Management of Stable Angina (Consultant)	1997-1998
ACC/AHA Committee to Develop Guidelines for the Management of Unstable Angina (Consultant)	1998-1999
ACC/AHA/NASPE Committee to Update Guidelines for Implantation of Pacemakers and Antiarrhythmia Devices	2000-2001

Mark Andrew Hlatky, MD/Page 6

ACC/AHA/HRS Committee on Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities	2006-2007
ACC/AHA Committee on Guidelines for Assessment of Cardiovascular Risk in Asymptomatic Adults	2008-2009
ACC/AHA/HRS Guideline for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death	2016-2017
ACC/AHA Guideline for the Management of Blood Cholesterol	2017-2018
5. <i>Data and Safety Monitoring Committees</i>	
Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study	1987-1989
Department of Veterans Affairs Cooperative Study in Health Services Number 8: Can the Provision of Primary Care Reduce Hospital Readmissions?	1992-1995
National Heart, Lung, and Blood Institute Mode Selection Trial in Sinus Node Dysfunction (MOST)	1995-2001
National Heart, Lung, and Blood Institute Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE)	1999-2004
National Heart, Lung, and Blood Institute Prospective Assessment After Pediatric Catheter Ablation	1999-2002
Agency for Healthcare Research and Quality Medicine or Surgery? (MS)	2000-2003
National Heart, Lung, and Blood Institute Surgical Treatment for Ischemic Heart Failure (STICH)	2002-2016
KAI Pharmaceuticals Direct Inhibition of * Protein Kinase C Enzyme to Limit Total Infarct Size in Acute Myocardial Infarction (DELTA MI)	2004-2006
National Heart, Lung, and Blood Institute Claudication: Exercise Versus Endoluminal Revascularization (CLEVER)	2006-2012

Mark Andrew Hlatky, MD/Page 7

Mayo Clinic, National Heart, Lung, and Blood Institute Tailored Antiplatelet Initiation to Lessen Outcomes Due to Decreased Clopidogrel Response after Percutaneous Coronary Intervention (TAILOR-PCI)	2013-present
Intermountain Heart Institute Effectiveness of a Proactive Cardiovascular Primary Prevention Strategy, With or Without the use of <u>C</u> oronary <u>C</u> alcium Screening, in Preventing Future Major Adverse Cardiac Events (CorCal Study)	2018-present
<i>6. Multicenter Randomized Clinical Trials and Clinical Registries</i>	
Bypass Angioplasty Revascularization Investigation (BARI) Economic and Quality of Life Evaluation Subcommittee (Chairman)	1987-2003
Endpoints Committee	1987-2003
Central Laboratory, Ancillary Study of Economics and Quality of Life (Director)	1988-2003
Policy Committee	1988-2003
Operations Committee	1988-2003
VA Non-Q wave Infarction Strategies in Hospital (VANQWISH) Planning Committee	1990-1992
Cost-Effectiveness Consultant	1992-2002
Executive Committee	1992-2002
Heart Estrogen/Progestin Replacement Study (HERS) Assistant Director for Cardiovascular Disease Endpoints Quality of Life Committee (Chairman)	1992-1999 1992-2002
Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI-2D) Operations Committee	2000-2009
Central Economics Laboratory (Director)	2000-2009
Vest Prevention of Early Sudden Death Trial and Prediction of ICD Therapies Study (VEST/PREDICTS) Steering Committee	2007-2011
Vest Prevention of Early Sudden Death Trial (VEST)	2011-2013
American College of Cardiology Society of Thoracic Surgeons Database Collaboration on the Comparative Effectiveness of Revascularization Strategies (ASCERT) Steering Committee	2012-2015

Mark Andrew Hlatky, MD/Page 8

7. Professional Society Activities

American College of Cardiology	
Angioplasty Database Subcommittee	1988-1989
Economics of Health Care Delivery Committee	1989-1994
Database Committee	1989-1996
Expert Consensus Panel, “Competence in Coronary Interventional Procedures”	1996-1997
Task Force on Performance Measures	1998-1999
Congestive Heart Failure Performance Measures Working Group	1998-2002
Task Force on Clinical Expert Consensus Documents	2000-2011
District Counselor, California Chapter	2006-2012
ICD Registry Research and Publications Subcommittee	2006-2013
Task Force on Clinical Practice Guidelines	2014-2020
Clinical Policy Approval Committee	2016-2018
American Heart Association	
Clinical Cardiology Council (Fellow)	1985-Present
Epidemiology and Prevention Council	2000-Present
Quality of Care and Outcomes Research Expert Panel	2000-2002
Quality of Care and Outcomes Research Interdisciplinary Working Group	2003-2010
Expert Panel on Subclinical Atherosclerotic Disease and Emerging Risk Factors	2006-2009
Quality of Care and Outcomes Research Council	2010-Present
Scientific Advisory Task Force	2011-2012
Research Committee	2013-2015
Task Force on Clinical Practice Guidelines	2014-2020
Distinguished Scientists Selection Committee	2017-2019
Heart Rhythm Society	
ICD Registry Research and Publications Subcommittee	2006-2008
Sudden Cardiac Arrest 360 Task Force	2007-2009

Major Grants as Principal Investigator

Robert Wood Johnson Foundation	1988-1998
Study of Economics and Quality of Life (SEQOL) in Patients Randomized to Coronary Artery Bypass Surgery or Coronary Angioplasty	
AHRQ (HS08362)	1994-2000
Cardiac Arrhythmia and Risk of Sudden Death Patient Outcome Research Team (PORT)	
AHRQ	1997-2002
Stanford-UCSF Evidence-based Practice Center	
NHLBI (HL58324)	1997-2003

Mark Andrew Hlatky, MD/Page 9

Cost and Quality of Life Outcomes after PTCA or CABG	
NHLBI (HL04130) Stanford Clinical Research Training Program (K30)	1999-2004
Donald W. Reynolds Foundation Genetic Epidemiology of Atherosclerotic Heart Disease: Advanced Strategies for Prevention and Therapy	2000-2006
NHLBI (HL61748) Economic Outcomes of Treatment Strategies in BARI-2D	2000-2008
AHRQ Comparative Effectiveness Review of Coronary Artery Stents Versus Coronary Bypass Graft Surgery	2006-2008
American Heart Association Stanford-Kaiser Cardiovascular Outcomes Research Center	2008-2013
NHLBI (HL099872) Improved Estimates of the Comparative Treatment Effects of CABG and PCI	2009-2012
NHLBI (HL139844) Preeclampsia to Cardiovascular Disease: Life-Course Analysis of Biomarkers and Risk	2018-2022

Invited Presentations (Selected):

Society for Clinical Trials Annual Meeting, Atlanta, GA, May 1987.

University of Indiana, Regenstrief Conference, "Quality and cost-conscious cardiovascular care," McCormick's Creek State Park, Indiana, October 1987.

Symposium on Computer Applications in Medical Care, Washington, DC, November 1987.

University of Indiana, Regenstrief Conference, "Methods for using large databases in health care: Problems and promises," Turkey Run State Park, Indiana, October 1989.

American Heart Association Annual Science Writer's Forum, San Antonio, TX, January 1990.

National Heart Lung and Blood Institute Symposium, "Rapid identification and treatment of acute myocardial infarction," Washington, DC, October 1990.

Agency for Health Care Policy and Research Conference, "Medical effectiveness research methods and data," Minneapolis, MN, September 1991.

Mark Andrew Hlatky, MD/Page 10

American College of Cardiology Annual Scientific Sessions. Panel participant, "Technology assessment," Dallas, TX, April 1992.

University of California, San Diego, Conference, "Echocardiography retreat," Williamsburg, VA, October 1992.

Cleveland Clinic Symposium, "Twenty-five years of coronary revascularization," Cleveland, OH, November 1992.

University of Utah Symposium, "New directions in the management of ventricular arrhythmias," Laguna Niguel, CA, August 1993.

University of Washington Conference, "Innovations in the treatment of heart disease," Whistler, BC, January 1994.

Society for Cardiac Angiography Annual Scientific Sessions, Plenary Lecture, "Cost-effectiveness analysis in clinical trials," Seattle, WA, May 1994.

Duke University School of Medicine Conference, "Cost-effective therapy symposium," Durham, NC, June 1994.

American Society for Anesthesiology, Annual Scientific Sessions, Plenary Lecture, "Outcomes research," San Francisco, CA, October 1994.

Society of Thoracic Surgeons Annual Meeting Symposium, "Risk management in CABG," Palm Springs, CA, January 1995.

University of Southern California, Cardiology Grand Rounds, Los Angeles, CA, April 1995.

University of Utah Conference, "Diagnosis and treatment of sustained ventricular tachyarrhythmias," Chatham, MA, August 1995.

University of Colorado Conference, "Enhancing quality of cardiovascular care," Keystone, CO, September 1995.

American Heart Association Annual Scientific Sessions, Plenary Session, "Long-term outcome in the trials comparing coronary bypass surgery and coronary angioplasty," Anaheim, CA, November 1995.

American Heart Association Annual Scientific Sessions, Cardiovascular Seminar, "Diagnostic testing in women," Anaheim, CA, November 1995.

University of California, San Francisco, Medical Grand Rounds, San Francisco, CA, January 1996.

University of Washington, Cardiology Grand Rounds, Seattle, WA, March 1996.

Mark Andrew Hlatky, MD/Page 11

American College of Cardiology Annual Scientific Sessions, Plenary Session, "How to best manage angina: What have we learned from the trials of medical therapy vs. PTCA vs. CABG," Orlando, FL, March 1996.

Society for Clinical Trials Annual Meeting, Pittsburgh, PA, May 1996.

North American Society of Pacing and Electrophysiology Annual Scientific Sessions. Mini-Course, "State of the art: Clinical application of implantable cardioverter defibrillator therapy," Seattle, WA, May 1996.

American College of Cardiology Conference, Chair of Conference, "Cardiovascular data standards," Bethesda, MD, June 1996.

Bowman Gray School of Medicine Conference, "Geriatrics educational retreat in cardiology," Banff, Alberta, August 1996.

University of Colorado Conference, "Enhancing quality of cardiovascular care," Vail, CO, September 1996.

United States Public Health Service Conference, "Enhancing cost-effectiveness in health and medical care," Bethesda, MD, November 1996.

American College of Cardiology Conference, "Economics and cardiovascular care," San Diego, CA, February 1997.

American College of Cardiology Annual Scientific Sessions, Core Curriculum, "Maintaining quality and the cost-effective practice of cardiology," Anaheim, CA, March 1997.

Duke University Conference, "Cost-effectiveness in medicine," St. Petersburg, FL, April 1997.

North American Society of Pacing and Electrophysiology Annual Scientific Sessions, Core Curriculum, "Clinical trials in ventricular tachyarrhythmias," New Orleans, LA, May 1997.

Saint Paul-Ramsey Medical Center, Cardiology Grand Rounds, Saint Paul, MN, July 1997.

Texas Heart Institute, Cardiology Grand Rounds, Houston, TX, September 1997.

University of California San Francisco Conference, "Design and methods of clinical trials," San Francisco, CA, October 1997

Association for Pharmacoeconomic and Outcomes Research Conference, "The ISPOR Lipid Conference," Orlando, FL, November 1997.

American Heart Association Annual Scientific Sessions, Cardiovascular Seminar, "Issues in ICD therapy," Orlando, FL, November 1997.

University of California San Diego, Cardiology Grand Rounds, San Diego, CA, March 1998.

Mark Andrew Hlatky, MD/Page 12

American College of Cardiology Annual Scientific Sessions, Mini-Course, "Cost-effective diagnostic testing in suspected coronary artery disease," Atlanta, GA, March 1998.

American College of Cardiology Annual Scientific Sessions, Meet the Experts, "Practical use of quality of life testing," Atlanta, GA, March 1998.

Ischemia Research and Education Foundation Symposium, "New frontiers in cardiac surgery," Seattle, WA, April 1998.

American Thoracic Society Conference, "Assessing costs and cost-effectiveness in critical care," San Diego, CA, May 1998.

University of California San Francisco, Cardiology Grand Rounds, San Francisco, CA, February 1999.

Phoenix Group Healthcare Outcomes Conference, "Outcomes beyond 2000," Phoenix, AZ, February 1999.

Duke Clinical Research Institute Conference, "Genetics of cardiovascular disease," Lansdowne, VA, April 1999.

North American Society of Pacing and Electrophysiology Annual Scientific Sessions, Core Curriculum, "Advances in dual-chamber ICDs," Toronto, ON, May 1999.

North American Society of Pacing and Electrophysiology Annual Scientific Sessions, Clinical Tutorial, "Cost-effectiveness of recently completed ICD trials," Toronto, ON, May 1999.

American Heart Association Scientific Forum, "Cardiovascular disease and stroke, quality of care and outcomes research," San Diego, CA, May 1999.

Kaiser Permanente Conference, "Cardiovascular medicine and surgery conference," Monterey, CA, September 1999.

American Heart Association Annual Scientific Sessions, Plenary Session, "New paradigms in acute coronary syndromes," Atlanta, GA, November 1999.

Fondazione Arturo Pinna Pintor Symposium, "Costs and risks of heart surgery," Turin, Italy, January 2000.

Society of Geriatric Cardiology Symposium, "Heart disease in the octogenarian," Anaheim, CA, March 2000.

Ninth International Symposium on Long-Term Clinical Trials, "Advanced issues in the design and conduct of randomized clinical trials," London, England, June 2000.

American Heart Association Annual Scientific Sessions, Cardiovascular Seminar, "Treatment of ST-segment elevation MI," New Orleans, LA, November 2000.

Mark Andrew Hlatky, MD/Page 13

American College of Cardiology Annual Scientific Sessions, Symposium, "Lessons from angioplasty versus surgery in multivessel disease: Have our conclusions changed with extended long-term follow-up?" Orlando, FL, March 2001.

National Academies Conference (Board on Science, Technology, and Economic Policy; Board on Health Care Services), "Medical innovation in the changing healthcare marketplace," Washington, DC, June 2001.

American College of Cardiology Annual Scientific Sessions, Meet the Experts, "Should we screen for asymptomatic coronary disease. And, if so, how?" Atlanta, GA, March 2002.

National Heart Lung and Blood Institute Workshop, "Women and ischemia syndrome Evaluation," Baltimore, MD, October 2002.

Mayo Clinic, Cardiovascular Division, Visiting Professor, Rochester, MN, November 2002.

Centers for Medicare and Medicaid Services, Medicare Coverage Advisory Committee Meeting, Baltimore, MD, February 2003.

Duke Clinical Research Institute Conference, "Economic analyses conducted alongside multinational clinical trials," Durham, NC, August 2003.

Kaiser Permanente Conference, "Cardiovascular medicine and surgery conference," Incline Village, NV, September 2003.

Heart Failure Society of America Annual Scientific Sessions, "Cost-effectiveness of device therapy in the heart failure patient population," Las Vegas, NV, September 2003.

Singapore General Hospital Postgraduate Medical Institute International Conference, Keynote Speaker, "Evidence-based medicine in practice," Singapore, October 2003.

Fudan University, Center for Evidence-Based Medicine, Visiting Professor, Shanghai, People's Republic of China, December 2003.

Heart Rhythm Society Annual Scientific Sessions, Core Curriculum, "Sudden cardiac death revisited," San Francisco, CA, May 2004.

Duke Clinical Research Institute Conference, "Implantable cardioverter defibrillators and cardiac resynchronization therapy," Washington, DC, August 2004.

University of Texas Southwestern, Visiting Professor, Dallas, TX, September 2004.

International Cardiology Forum, Brussels, Belgium, October 2004.

University of California, San Francisco, Medical Grand Rounds, San Francisco, CA, October 2004.

Mark Andrew Hlatky, MD/Page 14

American Heart Association Annual Scientific Sessions, How-To Session, "Integrating cost-effectiveness analysis into research," New Orleans, LA, November 2004.

Duke Clinical Research Institute Conference, "Cost-effectiveness of implantable cardioverter defibrillators and cardiac resynchronization therapy," Washington, DC, March 2005.

Heart Rhythm Society Annual Scientific Sessions, Featured Symposium, "Sudden cardiac death," New Orleans, LA, May 2005.

Tenth International Symposium on Long-Term Clinical Trials, "Advanced issues in the design and conduct of randomized clinical trials," Oxford, England, September 2005.

American College of Cardiology Annual Scientific Sessions, Spotlight Session, "Cardiac resynchronization therapy: All you need to know, 2006," Atlanta, GA, March 2006.

Duke Clinical Research Institute Conference, "Preventing tomorrow's sudden cardiac death today," Washington, DC, July 2006.

Canadian Cardiovascular Congress, Symposium, "New concepts in acute coronary syndromes: Beyond 2000," Vancouver, BC, October 2006.

European Society of Cardiology Congress, Symposium, "The use of cardiac rhythm devices in Europe and the USA: Why the huge gap?" Vienna, Austria, September 2007.

European Society of Cardiology Congress, Symposium, "New insights from 'old' trials: Long-term follow-up after coronary revascularization," Vienna, Austria, September 2007.

American College of Cardiology and Society for Cardiovascular Angiography and Interventions Joint Symposium, "A celebration of interventional cardiovascular medicine," Washington, DC, September 2007.

Columbia University Course, "Clinical trials in pulmonary arterial hypertension: Past, present, and future," Phoenix, AZ, October 2007.

American Heart Association Annual Scientific Sessions, Featured Lecture, "Leveraging insights into the risks, benefits, and costs of PCI in routine clinical practice," Orlando, FL, November 2007.

American Heart Association Annual Scientific Sessions, Plenary Session, "Overcoming clinical inertia: Improving cardiovascular care and eliminating disparities," Orlando, FL, November 2007.

American Diabetes Association Annual Advanced Postgraduate Course, "Pay for performance: update and evidence," San Francisco, CA, February 2008.

Centro de Estudios en Cardiología Intervencionista, International Cardiology Meeting, Otamendi Hospital, Buenos Aires, Argentina, October 2008.

Mark Andrew Hlatky, MD/Page 15

American College of Cardiology Annual Scientific Sessions, Plenary Session, "Late breaking clinical trials," Orlando, FL, March 2009.

American College of Cardiology Annual Scientific Sessions, Scientific Showcase, "Controversies in prevention: The JUPITER trial," Orlando, FL, March 2009.

Duke Clinical Research Institute Conference, "Race and ethnicity in cardiovascular clinical trials," Washington, DC, April 2009.

Society for Cardiovascular Angiography and Interventions Annual Scientific Sessions, Plenary Session, "PCI vs. medicine vs. CABG," Las Vegas, NV, May 2009.

Cardiovascular Research Foundation Conference, Transcatheter Cardiovascular Therapeutics 2009, "The symptomatic patient with multivessel disease: PCI vs. CABG," San Francisco, CA, September 2009.

Cardiovascular Research Foundation Conference, Transcatheter Cardiovascular Therapeutics 2009, "Meta-analysis and observational studies: Analysis through debate," San Francisco, CA, September 2009.

Cardiovascular Research Foundation Conference, Transcatheter Cardiovascular Therapeutics 2009, "Revascularization options in complex coronary artery disease: SYNTAX and BARI 2D," San Francisco, CA, September 2009.

Sierra Heart Institute Conference, "Trends in cardiovascular medicine: Cardiology for the primary physician," Donald A. Spring Honorary Lecture, Olympic Valley, CA, October 2009.

California Pacific Medical Center, Cardiology Grand Rounds, San Francisco, CA, November 2009.

American Heart Association Annual Scientific Sessions, Late Breaking Clinical Science, "Clinical trial focused update: BARI 2D and STICH," Orlando, FL, November 2009.

American Heart Association Annual Scientific Sessions, Special Session, "CRP in assessment and management of CVD risk," Orlando, FL, November 2009.

Centers for Disease Control and Prevention, Human Genetic Epidemiology Network Workshop, "Strengthening the reporting of genetic risk prediction studies," Atlanta, GA, December 2009.

Duke University, Duke Clinical Research Institute, Visiting Professor, Durham, NC, March 2010.

National Heart Lung and Blood Institute Workshop, "Screening for sudden cardiac death in the young," Bethesda, MD, April 2010.

American Heart Association, Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke, Scientific Sessions, "Controversies in atrial fibrillation," Washington, DC, May 2010.

Mark Andrew Hlatky, MD/Page 16

Harvard School of Public Health, Program in Cardiovascular Epidemiology Seminar, "Evaluation of novel risk markers," Boston, MA, June 2010.

National Heart Lung and Blood Institute, Workshop Co-Chair, "Future directions for CVD comparative effectiveness research," Washington, DC, July 2010.

Latin American Society of Interventional Cardiology, 2010 Scientific Congress, Buenos Aires, Argentina, August 2010.

National Institutes of Health and Agency for Healthcare Research and Quality Conference, "Methodologic challenges in comparative effectiveness research," Washington, DC, December 2010.

University of California, Los Angeles, Visiting Professor, Los Angeles, CA, January 2011.

New York University, Cardiology Grand Rounds, New York, NY, February 2011.

International Cardiologist and Rheumatologist Focus on Inflammation: A Shared Concern, Prato, Italy, June 2011.

Lancet/JACC Asia Pacific Cardiovascular Summit, "Breakthroughs and controversies," Hong Kong, China, July 2011.

Mid-America Heart Institute, Cardiology Grand Rounds, Kansas City, MO, October 2011.

University of California, San Francisco, Cardiology Grand Rounds, San Francisco, CA, October 2011.

American Heart Association Annual Scientific Sessions, Cardiovascular Seminar, "Defining a comparative effectiveness agenda for peripheral vascular disease in 2011," Orlando, FL, November 2011.

University of California, San Francisco Symposium, "Policy, science, and resources for comparative effectiveness research," San Francisco, CA, January 2012.

American College of Cardiology Annual Scientific Sessions, Symposium "Personalized medicine and the future of medical care," Chicago, IL, March 2012.

Society of Cardiovascular Computed Tomography Annual Scientific Meeting, Session "Contemporary controversies in cardiac CT," Baltimore, MD, July 2012.

Christiana Care Health System, Cardiology Grand Rounds, Wilmington, DE, July 2012.

American College of Cardiology International Program, "Best of ACC cardiovascular medicine. Major topics in cardiology today," Chennai, India; New Delhi, India; Kathmandu, Nepal; Dhaka, Bangladesh, August 2012.

Mark Andrew Hlatky, MD/Page 17

Agency for Healthcare Research Stakeholder Panel Meeting, “Decision analysis and computer simulation research priorities,” Rockville, MD, February 2013.

Northern California Medical Associates, “George L. Smith Keynote Address” at the Regional Primary Care Spring Symposium, Santa Rosa, CA, April 2013.

Institute of Medicine Workshop, “Observational studies in a learning health system,” Washington, DC, April 2013.

Annual European Congress of Rheumatology, Symposium “Cardiovascular risk in inflammatory arthritis,” Madrid, Spain, June 2013.

Society of Cardiovascular Computed Tomography Annual Scientific Meeting, Session “You be the judge: Four skeptics debate themselves,” Montreal, Canada, July 2013.

Cardiac Safety Research Consortium Think Tank, “Cardiac event adjudication,” Silver Spring, MD, November 2013.

American Heart Association Annual Scientific Sessions, Plenary Session, “Novel oral anticoagulants: Clinical conundra,” Dallas, TX, November 2013.

American Heart Association Annual Scientific Sessions, Ask the Experts Session, “Interpreting the literature: A primer on the do’s and don’ts,” Dallas, TX, November 2013.

Cleveland Clinic Heart and Vascular Institute, Visiting Professor, Cleveland, OH, January 2014.

Cardiac Safety Research Consortium Think Tank, “Randomized cardiovascular safety outcome studies,” Washington, DC, February 2014.

American College of Cardiology Annual Scientific Sessions, Plenary Session, “The role of the heart team in the treatment of stable ischemic heart disease,” Washington, DC, March 2014.

Danish Society of Cardiology Annual Meeting, Keynote Speaker, “State of the art: PCI or CABG,” Nyborg, Denmark, May 2014.

London School of Hygiene and Tropical Medicine, Seminar, “Comparative effectiveness of CABG and PCI: A moving target.” London, England, June 2014.

University of Copenhagen, Seminar, “Why didn’t they take my paper? An insider talks about medical journals.” Copenhagen, Denmark, September 2014.

American Heart Association Annual Scientific Sessions, Special Session, “AHA Strategically Focused Network: Directions for prevention and what does it take to be successful?” Chicago, IL, November 2014.

Mt. Sinai Cardiovascular Institute, Anandi L. Sharma Visiting Professor, Simon Dack Memorial Lecturer, “Comparative effectiveness of CABG and PCI.” New York, NY, December 2014.

Mark Andrew Hlatky, MD/Page 18

European Society of Cardiology, Cardiovascular Roundtable Workshop, “Composite and surrogate endpoints for cardiovascular clinical trials in heart failure, Munich, Germany, January 2015.

American College of Cardiology Annual Scientific Sessions, Special Session, “Diabetes: New concepts and TACTful debates,” San Diego, CA, March 2015.

American College of Cardiology Annual Scientific Sessions, Special Session, “Evaluating evidence in acute coronary syndrome trials,” San Diego, CA, March 2015.

International Society for Pharmacoeconomics and Outcomes Research Annual International Meeting, Plenary Session, “Cost-effectiveness and clinical practice guidelines: Have we reached a tipping point?” Philadelphia, PA, May 2015.

Academy of Medicine of Rio Grande do Sul, Keynote Speaker, “The next decade in cardiology,” Porto Alegre, Brazil, September 2015.

Cardiovascular Research Foundation Conference, Transcatheter Cardiovascular Therapeutics 2015, “Late-breaking clinical trials,” San Francisco, CA, October 2015.

University of Minnesota, Visiting Professor, Minneapolis, MN, December 2015.

Columbia University, Forum on Precision Medicine and Economics, New York, NY, December 2015.

American College of Cardiology Annual Scientific Sessions, Special Topics, “PCSK9 inhibitors and Entresto: Who should get these expensive new drugs and what are the economic implications?” Chicago, IL, April 2016.

European Society of Cardiology, Cardiovascular Round Table Workshop, “Acute coronary syndromes: Early diagnosis and consequences.” Paris, France, June 2016.

National Academy of Medicine, “Recommendations of the second panel on cost-effectiveness in health and medicine,” Washington, DC, December 2016.

Global Health Economics Colloquium, “The economics of non-communicable diseases,” San Francisco, CA, February 2017.

University of Bologna, “An overview of cost-effectiveness analysis,” Bologna, Italy, July 2017.

American Heart Association, “Precision medicine workshop,” Philadelphia, PA, October 2017.

Duke Margolis Center for Health Policy, “Working towards a repository of shareable cost-effectiveness analysis models,” Washington, DC, November 2017.

KDIGO (Kidney Disease Improving Global Outcomes) Conference, “Controversies in coronary artery and valvular diseases in chronic kidney disease,” Vienna, Austria, June 2018.

Mark Andrew Hlatky, MD/Page 19

Duke Clinical Research Institute/Stanford Center for Clinical Research Conference, “Clinical event classification summit,” Chicago, IL, September 2018.

American College of Cardiology, American Geriatrics Society, and National Institutes of Health Workshop, ‘Diagnostic testing in older adults with cardiovascular disease,’ Washington,, DC, October 2018.

American Heart Association Scientific Sessions, Cardiovascular Seminar, “Deep dive into the 2018 cholesterol guidelines: Risk, cost-effectiveness, and cases.” Chicago, IL, November 2018.

American Heart Association Scientific Sessions, Plenary Session, “Prevention beyond the guidelines: What to do next?” Chicago, IL, November 2018.

BIBLIOGRAPHY

REFEREED JOURNALS

1. Hlatky MA, Hulley S. Plasma cholesterol. Can it be too low? *Arch Intern Med* 1981;141:1132.
2. Hlatky M, Botvinick E, Brundage B. Diagnostic accuracy of cardiologists compared with probability calculations using Bayes' rule. *Am J Cardiol* 1982;49:1927-1931.
3. Hlatky M, Botvinick E, Brundage B. The independent value of exercise thallium scintigraphy to physicians. *Circulation* 1982; 66:953-959.
4. Hlatky MA. Is renal biopsy necessary in adults with nephrotic syndrome? *Lancet* 1982; 2:1264-1268.
5. Hlatky MA, Califf RM, Kong Y, Harrell FE Jr, Rosati RA. Natural history of patients with single vessel disease suitable for percutaneous transluminal coronary angioplasty. *Am J Cardiol* 1983; 52: 225-229.
6. Hlatky MA, Lee KL, Botvinick EH, Brundage BH. Diagnostic test use in different practice settings: A controlled comparison. *Arch Intern Med* 1983;143:1886-1889.
7. Mark DB, Califf RM, Morris KG, Harrell FE Jr, Pryor DB, Hlatky MA, Lee KL, Rosati RA. Clinical characteristics and long-term survival of patients with variant angina. *Circulation* 1984; 69:880-888.
8. Hlatky MA, Pryor DB, Harrell FE Jr, Califf RM, Mark DB, Rosati RA. Factors affecting sensitivity and specificity of exercise electrocardiography. Multivariable analysis. *Am J Med* 1984; 77:64-71.
9. Hlatky MA, Lee KL, Harrell FE Jr, Califf RM, Pryor DB, Mark DB, Rosati RA. Tying clinical research to patient care by use of an observational database. *Stat Med* 1984;3:375-384.
10. Hlatky MA, Califf RM, Lee KL, Pryor DB, Wagner GS, Rosati RA. Prognostic significance of precordial ST-segment depression during inferior acute myocardial infarction. *Am J Cardiol* 1985; 55:325-329.
11. Pryor DB, Califf RM, Harrell FE Jr, Hlatky MA, Lee KL, Mark DB, Rosati RA. Clinical data bases: Accomplishments and unrealized potential. *Med Care* 1985;23:623-647.
12. Moorman JR, Hlatky MA, Eddy DM, Wagner GS, Duke Medical House Staff. The yield of the routine admission electrocardiogram: A study in a general medical service. *Ann Intern Med* 1985; 103:590-595.
13. Califf RM, Hlatky MA, Mark DB, Lee KL, Harrell FE Jr, Rosati RA, Pryor DB. Randomized trials of coronary artery bypass surgery: Impact on clinical practice at Duke University Medical Center. *Circulation* 1985;72(Suppl V):136-144.

Mark Andrew Hlatky, MD/Page 21

14. Morris PB, Imber MJ, Heinsimer JA, Hlatky MA, Reimer KA. Rheumatoid arthritis and coronary arthritis. *Am J Cardiol* 1986;57:689-690.
15. Hlatky MA. Evaluation of diagnostic tests. *J Chronic Dis* 1986;39:357-358.
16. Kates RA, Stack RS, Hill RF, Carlson EB, Hinohara T, Hlatky MA, Reves JG. General anesthesia for patients undergoing percutaneous transluminal coronary angioplasty during acute myocardial infarction. *Anesth Analg (Cleve)* 1986;65:815-818.
17. Hlatky MA, Fleg JL, Hinton PC, Lakatta EG, Marcus FI, Smith TW, Strauss HC. Physician practice in the management of congestive heart failure. *J Am Coll Cardiol* 1986;8:966-970.
18. Hlatky MA. Exercise stress testing to screen for coronary artery disease in asymptomatic persons. *J Occup Med* 1986;28:1020-1025.
19. Hlatky MA, Haney T, Barefoot JC, Califf RM, Mark DB, Pryor DB, Williams RB. Medical, psychological and social correlates of work disability among men with coronary artery disease. *Am J Cardiol* 1986;58:911-915.
20. Papanicolaou MN, Califf RM, Hlatky MA, McKinnis RA, Harrell FE Jr, Mark DB, McCants B, Rosati RA, Lee KL, Pryor DB. Prognostic implications of angiographically normal and insignificantly narrowed coronary arteries. *Am J Cardiol* 1986;58:1181-1187.
21. Mark DB, Hlatky MA, Lee KL, Harrell FE Jr, Califf RM, Pryor DB. Localizing coronary artery obstructions with the exercise treadmill test. *Ann Intern Med* 1987;106:53-55.
22. Hlatky MA, Mark DB, Harrell FE Jr, Lee KL, Califf RM, Pryor DB. Rethinking sensitivity and specificity. *Am J Cardiol* 1987;59:1195-1198.
23. Mark DB, Hlatky MA, Harrell FE Jr, Lee KL, Califf RM, Pryor DB. Exercise treadmill score for predicting prognosis in coronary artery disease. *Ann Intern Med* 1987;106:793-800.
24. Slater DK, Hlatky MA, Mark DB, Harrell FE Jr, Pryor DB, Califf RM. Outcome in suspected acute myocardial infarction with normal or minimally abnormal admission electrocardiographic findings. *Am J Cardiol* 1987;60:766-770.
25. Pryor DB, Harrell FE Jr, Rankin JS, Lee KL, Muhlbaier LH, Oldham HN, Hlatky MA, Mark DB, Reves JG, Califf RM. The changing survival benefits of coronary revascularization over time. *Circulation* 1987;76(Suppl V):13-21.
26. Califf RM, Mark DB, Harrell FE Jr, Hlatky MA, Lee KL, Rosati RA, Pryor DB. Importance of clinical measures of ischemia in the prognosis of patients with documented coronary artery disease. *J Am Coll Cardiol* 1988;11:20-26.
27. Hlatky MA, Califf RM, Harrell FE Jr, Lee KL, Mark DB, Pryor DB. Comparison of predictions based on observational data with the results of randomized controlled trials of coronary artery bypass surgery. *J Am Coll Cardiol* 1988;11:237-245.

Mark Andrew Hlatky, MD/Page 22

28. Hlatky MA, Cotugno HE, O'Connor C, Mark DB, Pryor DB, Califf RM. Adoption of thrombolytic therapy in the management of acute myocardial infarction. *Am J Cardiol* 1988;61:510-514.
29. Hlatky MA, Cotugno HE, Mark DB, O'Connor CM, Califf RM, Pryor DB. Trends in physician management of uncomplicated acute myocardial infarction, 1970-1987. *Am J Cardiol* 1988; 61:515-518.
30. Stack RS, Califf RM, Hinohara T, Phillips HR, Pryor DB, Simonton CA, Carlson EB, Morris KG, Behar VS, Kong Y, Peter RH, Hlatky MA, O'Connor CM, Mark DB. Survival and cardiac event rates in the first year following emergency angioplasty for acute myocardial infarction. *J Am Coll Cardiol* 1988;11:1141-1148.
31. Navetta FI, Barber MJ, Gurbel PA, Moreadith RW, Bernstein R, Hlatky MA, Coleman RE, Bashore TM. Myocardial ischemia in constrictive pericarditis. *Am Heart J* 1988;116:1107-1111.
32. Bounous EP, Mark DB, Pollock BG, Hlatky MA, Harrell FE Jr, Lee KL, Rankin JS, Wechsler AS, Pryor DB, Califf RM. Surgical survival benefits for coronary disease patients with left ventricular dysfunction. *Circulation* 1988;78 (Suppl I):151-157.
33. Califf RM, Harrell FE Jr, Lee KL, Rankin JS, Mark DB, Hlatky MA, Muhlbaier LH, Wechsler AS, Jones RH, Oldham NH Jr, Pryor DB. Changing efficacy of coronary revascularization: Implications for patient selection. *Circulation* 1988;78 (Suppl I):185-191.
34. Mark DB, Hlatky MA, O'Connor CM, Pryor DB, Wall TC, Honan MB, Phillips HR III, Califf RM. Administration of thrombolytic therapy in the community hospital: Established principles and unresolved issues. *J Am Coll Cardiol* 1988;12 (Suppl A):32-43.
35. Davidson CJ, Hlatky M, Morris KG, Pieper K, Skelton TN, Schwab SJ, Bashore TM. Cardiovascular and renal toxicity of a nonionic radiographic contrast agent after cardiac catheterization: A prospective trial. *Ann Intern Med* 1989;110:119-124.
36. Schwab SJ, Hlatky MA, Pieper KS, Davidson CJ, Morris KG, Skelton TN, Bashore TM. Contrast nephrotoxicity: A randomized controlled clinical trial of a nonionic and an ionic contrast agent. *N Engl J Med* 1989;320:149-53.
37. Fleg JL, Hinton PC, Lakatta EG, Marcus FI, Smith TW, Strauss HC, Hlatky MA. Physician utilization of laboratory procedures to monitor outpatients with congestive heart failure. *Arch Intern Med* 1989;149:393-396.
38. Quigley PJ, Hlatky MA, Hinohara T, Rendall DS, Perez JA, Phillips HR, Califf RM, Stack RS. Repeat percutaneous transluminal coronary angioplasty and predictors of recurrent restenosis. *Am J Cardiol* 1989;63:409-413.
39. Wall TC, Mark DB, Califf RM, Collins G, Burgess R, Skelton TN, Hinohara T, Kong DF, Mantell S, Aronson L, Hlatky MA, Cusma J, Stack RS, Pryor DB, Bashore TM. Prediction of early recurrent ischemia and coronary reocclusion after successful thrombolysis: A qualitative and

Mark Andrew Hlatky, MD/Page 23

- quantitative angiographic study. *Am J Cardiol* 1989;63:423-428.
40. DeBruijn NP, Hlatky MA, Jacobs JR, Clements FM, Croughwell ND, Davis D, Flezzani P, Hill RF, Hinohara T, Kates RA, Karis JH, McIntyre W, Reves JG, Stack RS. General anesthesia during percutaneous transluminal coronary angioplasty for acute myocardial infarction: Results of a randomized controlled clinical trial. *Anesth Analg (Cleve)* 1989;68:201-207.
 41. O'Connor CM, Mark DB, Hinohara T, Stack RS, Rendall D, Hlatky MA, Pryor DB, Phillips HR III, Califf RM. Rescue coronary angioplasty after failure of intravenous streptokinase in acute myocardial infarction: In-hospital and long-term outcomes. *J Invasive Cardiol* 1989;1:85-95.
 42. Califf RM, Harrell FE Jr, Lee KL, Rankin JS, Hlatky MA, Mark DB, Jones RH, Muhlbaier LH, Oldham HN, Pryor DB. The evolution of medical and surgical therapy for coronary artery disease: A 15-year perspective. *JAMA* 1989;261:2077-2086.
 43. Kong DF, Lee KL, Harrell FE Jr, Boswick JM, Mark DB, Hlatky MA, Califf RM, Pryor DB. Clinical experience and predicting survival in coronary disease. *Arch Intern Med* 1989; 149:1177-1181.
 44. Hlatky MA, Mark DB, Califf RM, Pryor DB. Angina, myocardial ischemia and coronary disease: Gold standards, operational definitions and correlations. *J Clin Epidemiol* 1989;42:381-384.
 45. Barefoot JC, Peterson BL, Harrell FE Jr, Hlatky MA, Pryor DB, Haney TL, Blumenthal JA, Siegler IC, Williams RB Jr. Type A behavior and survival: A follow-up study of 1427 patients with coronary artery disease. *Am J Cardiol* 1989;64:427-432.
 46. Hlatky MA, Boineau RE, Higginbotham MB, Lee KL, Mark DB, Califf RM, Cobb FR, Pryor DB. A brief self-administered questionnaire to determine functional capacity (The Duke Activity Status Index). *Am J Cardiol* 1989;64:651-654.
 47. Hlatky MA, Selker HP. Projects and priorities in cardiovascular modeling. *J Am Coll Cardiol* 1989; 14:52A-56A.
 48. Mark DB, Hlatky MA, Califf RM, Morris JJ Jr, Sisson SD, McCants CB, Lee KL, Harrell FE Jr, Pryor DB. Painless exercise ST deviation on the treadmill: Long-term prognosis. *J Am Coll Cardiol* 1989;14:885-892.
 49. Honan MB, Bengtson JR, Pryor DB, Rendall DS, Stack RS, Hinohara T, Skelton TN, Califf RM, Hlatky MA, Mark DB. Exercise treadmill testing is a poor predictor of anatomic restenosis after angioplasty for acute myocardial infarction. *Circulation* 1989;80:1585-1584.
 50. Siegel WC, Mark DB, Hlatky MA, Harrell FE Jr, Pryor DB, Barefoot JC, Williams RB Jr. Clinical correlates and prognostic significance of Type A behavior and silent myocardial ischemia on the treadmill. *Am J Cardiol* 1989;64:1280-1283.
 51. Hlatky MA, Califf RM, Harrell FE Jr, Lee KL, Mark DB, Muhlbaier LH, Pryor DB. Clinical judgment and therapeutic decision making. *J Am Coll Cardiol* 1990; 15:1-14. (Reprinted in

Mark Andrew Hlatky, MD/Page 24

- Knoebel SB, Dack S, eds. An era in cardiovascular medicine. New York: Elsevier Science Publishing, 1991:303-315.)
52. Bengtson JR, Mark DB, Honan MB, Rendall DS, Hinohara T, Stack RS, Hlatky MA, Califf RM, Lee KL, Pryor DB. Detection of restenosis after elective percutaneous transluminal coronary angioplasty using the exercise treadmill test. *Am J Cardiol* 1990;65:28-34.
 53. Hlatky MA, Greenfield JC Jr. Technologic innovation and care of the elderly patient with cardiovascular disease: How will the DRG system respond? *Am J Med* 1990;88:1-1N-1-2N.
 54. Lee JC, Bengtson JR, Lipscomb J, Bashore TM, Mark DB, Califf RM, Pryor DB, Hlatky MA. Feasibility and cost-saving potential of outpatient cardiac catheterization. *J Am Coll Cardiol* 1990; 15:378-384.
 55. Davidson CJ, Mark DB, Pieper KS, Kisslo KB, Hlatky MA, Gabriel DA, Bashore TM. Thrombotic and cardiovascular complications related to nonionic contrast media during cardiac catheterization: Analysis of 8517 patients. *Am J Cardiol* 1990;65:1481-1484.
 56. Robinson M, Blumenthal JA, Burber EJ, Hlatky M, Reves JG. Coronary artery bypass grafting and cognitive function: A review. *J Cardiac Rehabil* 1990;10:180-189.
 57. Siegel WC, Hlatky MA, Mark DB, Barefoot JC, Harrell FE Jr, Pryor DB, Williams RB Jr. The effect of type A behavior on exercise test outcome in coronary artery disease. *Am J Cardiol* 1990; 66:179-182.
 58. Honan MB, Harrell FE Jr, Reimer KA, Califf RM, Mark DB, Pryor DB, Hlatky MA. Cardiac rupture, mortality, and the timing of thrombolytic therapy: A meta-analysis. *J Am Coll Cardiol* 1990;16:359-367.
 59. Hlatky MA, Morris KG, Pieper KS, Davidson CJ, Schwab SJ, Bashore TM. Randomized comparison of the cost and effectiveness of iopamidol and diatrizoate as contrast agents for cardiac angiography. *J Am Coll Cardiol* 1990;16:871-877.
 60. Hlatky MA, Lipscomb J, Nelson C, Califf RM, Pryor DB, Wallace AG, Mark DB. Resource use and cost of initial coronary revascularization: Coronary angioplasty versus coronary bypass surgery. *Circulation* 1990; 82(Suppl):IV-208-IV-213.
 61. Lee KL, Pryor DB, Pieper KS, Harrell FE Jr, Califf RM, Mark DB, Hlatky MA, Coleman RE, Cobb FR, Jones RH. The prognostic value of radionuclide angiography in medically treated patients with coronary artery disease: A comparison with clinical and catheterization variables. *Circulation* 1990; 82:1705-1723.
 62. Clemmensen P, Bates ER, Califf RM, Hlatky MA, Aronson L, George BS, Lee KL, Kereiakes DJ, Gacioch G, Berrios E, Topol EJ, TAMI Study Group. Complete atrio-ventricular block complicating inferior wall acute myocardial infarction treated with reperfusion therapy. *Am J Cardiol* 1991; 67:225-230.

Mark Andrew Hlatky, MD/Page 25

63. Hickey AR, Wenger TL, Carpenter VP, Tilson HH, Hlatky MA, Furberg CD, Kirkpatrick CH, Strauss HC, Smith TW. Digoxin immune Fab therapy in the management of digitalis intoxication: Safety and efficacy results of an observational surveillance study. *J Am Coll Cardiol* 1991; 17:590-598.
64. Hlatky MA. Using databases to evaluate therapy. *Stat Med* 1991;10:647-652.
65. Pryor DB, Shaw L, Harrell FE Jr, Lee KL, Hlatky MA, Mark DB, Muhlbaier LH, Califf RM. Estimating the likelihood of severe coronary artery disease. *Am J Med* 1991;90:553-562.
66. Mark DB, Shaw L, Harrell FE Jr, Hlatky MA, Lee KL, Bengtson JR, McCants CB, Califf RM, Pryor DB. Prognostic value of a treadmill exercise score in outpatients with suspected coronary artery disease. *N Engl J Med* 1991;325:849-853.
67. Nelson CL, Herndon JE, Mark DB, Pryor DB, Califf RM, Hlatky MA. Relationship of clinical and angiographic factors to functional capacity as measured by the Duke Activity Status Index. *Am J Cardiol* 1991;68:973-975.
68. Harding MB, Davidson CJ, Pieper KS, Hlatky M, Schwab SJ, Morris KG, Hermiller JB, Bashore TM. Comparison of cardiovascular and renal toxicity after cardiac catheterization using a nonionic versus ionic radiographic contrast agent. *Am J Cardiol* 1991;68:1117-1119.
69. Evans GT Jr, Scheinman MM, Bardy G, Borggrefe M, Brugada P, Fisher J, Fontaine G, Huang SKS, Huang WH, Josephson M, Kuck K-H, Hlatky MA, Levy S, Lister JW, Marcus F, Morady F, Tchou P, Waldo AL, Wood D. Predictors of in-hospital mortality after DC catheter ablation of the atrioventricular junction: Results of a prospective, international, multicenter study. *Circulation* 1991;84:1924-1937.
70. Hlatky MA, Whittemore AS. The importance of models in the assessment of synergy. *J Clin Epidemiol* 1991;44:1287-1288.
71. Blumenthal JA, Madden DJ, Burker EJ, Croughwell N, Schniebolk S, Smith R, White WD, Hlatky M, Reves JG. A preliminary study of the effects of cardiac procedures on cognitive performance. *Int J Psychosom Med* 1991;38:13-16.
72. Williams RB, Barefoot JC, Califf RM, Haney TL, Saunders WB, Pryor DB, Hlatky MA, Siegler IC, Mark DB. Prognostic importance of social and economic resources among patients with angiographically documented coronary artery disease. *JAMA* 1992;267:520-524.
73. Mark DB, Lam LC, Lee KL, Clapp-Channing NE, Williams RB, Pryor DB, Califf RM, Hlatky MA. Identification of patients with coronary disease at high risk for loss of employment: A prospective validation study. *Circulation* 1992;86:1485-1494.
74. Dudley RA, Harrell FE Jr, Smith LR, Mark DB, Califf RM, Pryor DB, Glower D, Lipscomb J, Hlatky MA. Comparison of analytic models for estimating the effect of clinical factors on the cost of coronary artery bypass graft surgery. *J Clin Epidemiol* 1993;46:261-271.

Mark Andrew Hlatky, MD/Page 26

75. Hlatky MA. Economic evaluation of low osmolality contrast media. *J Am Coll Cardiol* 1993; 21:1710-1711.
76. Mark DB, Lam LC, Lee KL, Jones RH, Pryor DB, Stack RS, Williams RB, Clapp-Channing NE, Califf RM, Hlatky MA. Effects of coronary angioplasty, coronary bypass surgery, and medical therapy on employment in patients with coronary artery disease: A prospective comparison study. *Ann Intern Med* 1994;120:111-117.
77. Pilote L, Racine N, Hlatky MA. Differences in the treatment of myocardial infarction in the United States and Canada: A comparison of two university hospitals. *Arch Intern Med* 1994;154:1090-1096.
78. Jaeger AA, Hlatky MA, Paul SM, Gortner SR. Functional capacity after cardiac surgery in elderly patients. *J Am Coll Cardiol* 1994;24:104-108.
79. Ritchie JL, Cheitlin MD, Hlatky MA, Ryan TJ, Williams RG. Profile of the cardiovascular specialist: trends in needs and supply and implications for the future. *J Am Coll Cardiol* 1994; 24:313-321.
80. Gortner SR, Jaeger AA, Harr J, Hlatky MA. Elders' recovery from cardiac surgery: Is gender a factor? *J Myocard Ischemia* 1994; 6(9):17-25.
81. Mark DB, Naylor CD, Hlatky MA, Califf RM, Topol EJ, Granger CB, Knight JD, Nelson CL, Lee KL, Clapp-Channing NE, Sutherland W, Pilote L, Armstrong PW. Use of medical resources and quality of life after acute myocardial infarction in Canada and the United States. *N Engl J Med* 1994;331:1130-1135.
82. Omoigui NA, Marcus FI, Mason JW, Hahn EA, Hartz VL, Hlatky MA. Cost of initial therapy in the Electrophysiologic Study versus ECG Monitoring Trial (ESVEM). *Circulation* 1995;91:1070-1076.
83. Hlatky MA, Charles ED, Nobrega F, Gelman K, Johnstone I, Melvin J, Ryan T, Wiens R, Pitt B, Reeder G, Smith H, Whitlow P, Zorn G, Frid DJ, Mark DB, BARI Study Group. Initial functional and economic status of patients with multivessel coronary disease randomized in the Bypass Angioplasty Revascularization Investigation (BARI). *Am J Cardiol* 1995;75:34C-41C.
84. Hlatky MA. Patient preferences and clinical guidelines. *JAMA* 1995;273:1219-1220.
85. Mark DB, Hlatky MA, Califf RM, Naylor CD, Lee KL, Armstrong PW, Barbash G, White H, Simoons ML, Nelson CL, Clapp-Channing N, Knight JD, Harrell FE Jr, Simes J, Topol EJ. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. *N Engl J Med* 1995;332:1418-1424.
86. Pilote L, Granger C, Armstrong PW, Mark DB, Hlatky MA. Differences in the treatment of myocardial infarction between the United States and Canada: A survey of physicians in the GUSTO trial. *Med Care* 1995;33:598-610.

Mark Andrew Hlatky, MD/Page 27

87. Pilote L, Hlatky MA. Attitudes of women towards hormone therapy and prevention of heart disease. *Am Heart J* 1995;129:1237-1238.
88. Mason JJ, Owens DK, Harris RA, Cooke JP, Hlatky MA. The role of coronary angiography and coronary revascularization before non-cardiac vascular surgery. *JAMA* 1995;273:1919–1925.
89. Smith SC, Blair SN, Criqui MH, Fletcher GF, Fuster V, Gersh BJ, Gotto AM, Gould KL, Greenland P, Grundy SM, Hill MN, Hlatky MA, Houston-Miller N, Krauss RM, LaRosa J, Ockene IS, Oparil S, Pearson TA, Rapaport E, Starke RD, Secondary Prevention Panel. Preventing heart attack and death in patients with coronary disease. *Circulation* 1995;92:2-4. (Published simultaneously in *J Am Coll Cardiol* 1995;26:292–294, and reprinted in *Cardiovasc Nurs* 1996;32(4):26-28.)
90. Hlatky MA, Lam LC, Lee KL, Clapp–Channing NE, Williams RB, Pryor DB, Califf RM, Mark DB. Job strain and the prevalence and outcome of coronary artery disease. *Circulation* 1995;92:327-333.
91. Pilote L, Bourassa MG, Bacon C, Bost J, Detre K, Mark DB, Pitt B, Reeder G, Rogers WJ, Ryan T, Schwartz L, Smith H, Whitlow P, Wiens R, Hlatky MA. Better functional status in American than Canadian patients with heart disease: An effect of medical care? *J Am Coll Cardiol* 1995;26:1115–1120.
92. Williams JF Jr, Bristow MR, Fowler MB, Francis GS, Garson A Jr, Gersh BJ, Hammer DF, Hlatky MA, Leier CV, Packer M, Pitt B, Ulliyot DJ, Wexler LF, Winters WL Jr. Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the evaluation and management of heart failure). *J Am Coll Cardiol* 1995;26:1376–1398. (Published simultaneously in *Circulation* 1995;92:2764-2784.)
93. Sim I, Gupta M, McDonald K, Bourassa MG, Hlatky MA. A meta-analysis of randomized trials comparing coronary artery bypass grafting with percutaneous transluminal coronary angioplasty in multivessel coronary artery disease. *Am J Cardiol* 1995;76:1025–1029.
94. Hlatky MA. Analysis of costs associated with CABG and PTCA. *Ann Thorac Surg* 1996;61:530-532.
95. Hlatky MA. Cost and efficacy analysis in the ESVEM trial: Implications for diagnosis and therapy of ventricular tachyarrhythmias. *Prog Cardiovasc Dis* 1996;38:371-376.
96. Goldman L, Garber AM, Grover S, Hlatky MA. Cost-effectiveness of assessment and management of risk factors. *J Am Coll Cardiol* 1996;27:1020–1030.
97. Bypass Angioplasty Revascularization Investigation (BARI) Investigators (Writing Committee: Alderman EL, Andrews K, Bost J, Bourassa M, Chaitman BR, Detre K, Faxon DP, Follman D, Frye RL, Hlatky M, Jones RH, Kelsey SF, Rogers WR, Rosen AD, Schaff H, Sellers MA, Sopko G, Sutton-Tyrrell K, Williams DO). Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. *N Engl J Med* 1996;335:217-225.

Mark Andrew Hlatky, MD/Page 28

98. Every NR, Spertus J, Fihn SD, Hlatky M, Martin JS, Weaver WD. Length of hospital stay after acute myocardial infarction in the Myocardial Infarction Triage and Intervention (MITI) Project registry. *J Am Coll Cardiol* 1996;28:287-293.
99. Sim I, Hlatky MA. Growing pains of meta-analysis. *Br Med J* 1996;313:702-703.
100. Hlatky MA, Vaughn WK. Quality of life in patients with supraventricular arrhythmia. *Circulation* 1996;94:1491-1493.
101. Every NR, Parsons LS, Hlatky M, Martin JS, Weaver WD. A comparison of thrombolytic therapy with primary coronary angioplasty for acute myocardial infarction. *N Engl J Med* 1996;335:1253-1260.
102. Selby JV, Fireman BH, Lundstrom RJ, Swain BE, Truman AF, Wong CC, Froelicher ES, Barron HV, Hlatky MA. Variation among hospitals in coronary angiography practices and outcomes after myocardial infarction in a large health maintenance organization. *N Engl J Med* 1996;335:1888-1896.
103. Hlatky MA. Economic and ethical considerations in percutaneous coronary revascularization. *J Intervent Cardiol* 1996;9:469-473.
104. Owens DK, Sanders GD, Harris RA, McDonald KM, Heidenreich PA, Dembitzer AD, Hlatky MA. Cost-effectiveness of implantable cardioverter defibrillators relative to amiodarone for prevention of sudden cardiac death. *Ann Intern Med* 1997;126:1-12.
105. Hlatky MA, Rogers WJ, Johnstone I, Boothroyd D, Brooks MM, Pitt B, Reeder G, Ryan T, Smith H, Whitlow P, Wiens R, Mark DB. Medical care costs and quality of life after randomization to coronary angioplasty or coronary bypass surgery. *N Engl J Med* 1997;336:92-99.
106. Hlatky MA, Boothroyd DB, Johnstone IM, Marcus FI, Hahn E, Hartz V, Mason JW. Long-term cost-effectiveness of alternative management strategies for patients with life-threatening ventricular arrhythmias. *J Clin Epidemiol* 1997;50:185-194.
107. The Writing Group for the Bypass Angioplasty Revascularization Investigation (BARI) Investigators (Alderman EL, Andrews K, Bourassa M, Brooks MM, Chaitman BR, Detre K, Faxon DP, Follman D, Frye RL, Hlatky M, Jones RH, Kelsey SF, Rogers WJ, Rosen AD, Schaff H, Sellers MA, Sopko G, Sutton-Tyrrell K, Williams DO). Five-year clinical and functional outcome comparing bypass surgery and angioplasty in patients with multivessel coronary disease. A multicenter randomized trial. *JAMA* 1997;277:715-721.
108. Sim I, McDonald KM, Lavori PW, Norbutas CM, Hlatky MA. Quantitative overview of randomized trials of amiodarone to prevent sudden cardiac death. *Circulation* 1997;96:2823-2829.
109. Hlatky MA, Bacon C, Boothroyd D, Mahanna E, Reves JG, Newman MF, Johnstone I, Winston C, Brooks MM, Rosen AD, Mark DB, Pitt B, Rogers W, Ryan T, Wiens R, Blumenthal JA. Cognitive function five years after randomization to coronary angioplasty or coronary artery bypass graft surgery. *Circulation* 1997;96(Suppl II):11-15.

Mark Andrew Hlatky, MD/Page 29

110. Hlatky MA. Evaluation of chest pain in the emergency department. *N Engl J Med* 1997;1687-1689.
111. Every NR, Parsons L, Hlatky MA, McDonald KM, Thom D, Hallstrom AP, Martin JS, Weaver WD. Use and accuracy of state death certificates for classification of sudden cardiac death in high-risk populations. *Am Heart J* 1997;134:1129-1132.
112. Ferry DR, O'Rourke RA, Blaustein AS, Crawford MH, Deedwania PC, Carson PE, Pepine CJ, Thomas RG, Hlatky MA, Leppo JA, Iwane MK, Kleiger RE, Zoble RG, Dai H, Chow BK, Lavori PW, Boden WE. Design and baseline characteristics of the Veterans Affairs non-Q-wave infarction strategies in-hospital (VANQWISH) trial. *J Am Coll Cardiol* 1998;31:312-320.
113. Hirshfeld JW, Ellis SG, Faxon DP, Block PC, Carver JR, Douglas JS, Eigler NL, Hlatky MA, Holmes DR, Hutter AM, Jacobs AK, Johnson WL, Jollis JG, Kimmel SE, Laskey WK, Luft H, Malenka DJ, Oboler AA, Summers AE, Taussig AS. Recommendations for the assessment and maintenance of proficiency in coronary interventional procedures. Statement of the American College of Cardiology. *J Am Coll Cardiol* 1998;31:722-743.
114. Mason JW, Hlatky MA. Do patients prefer physiologic pacing? *N Engl J Med* 1998;338:1147-1148.
115. Gregoratas G, Cheitlin MD, Conill A, Epstein AE, Fellows C, Ferguson TB, Freedman RA, Hlatky MA, Nacarelli GV, Saksena S, Schlant RC, Silka MS. ACC/AHA guidelines for implantation of cardiac pacemakers and antiarrhythmia devices. *J Am Coll Cardiol* 1998;31:1175-1206 (Executive summary published concurrently in *Circulation* 1998;97:1325-1335).
116. Hlatky MA, Owens DK. Cost-effectiveness of tests to assess the risk of sudden death after acute myocardial infarction. *J Am Coll Cardiol* 1998;31:1490-1492.
117. Every NR, Hlatky MA, McDonald KM, Weaver WD, Hallstrom AP. Estimating the proportion of post-myocardial infarction patients who may benefit from prophylactic implantable defibrillator placement from analysis of the CAST Registry. *Am J Cardiol* 1998;82:683-685.
118. Hlatky MA, Boothroyd D, Horine S, Winston C, Brooks MM, Rogers W, Pitt B, Reeder G, Ryan T, Smith H, Whitlow P, Wiens R, Mark DB. Employment after coronary angioplasty or coronary bypass surgery in patients employed at the time of revascularization. *Ann Intern Med* 1998;129:543-547
119. Hlatky MA. Exercise testing to predict outcome in patients with angina. *J Gen Intern Med* 1999;14:63-65.
120. Sanders GD, Hagerty CG, Sonnenberg FA, Hlatky MA, Owens DK. Distributed decision support using a web-based interface: Prevention of sudden cardiac death. *Med Decis Making* 1999;19:157-166.
121. Heidenreich PA, Hlatky MA. Evaluation of risk in patients with chest pain presenting to the emergency department. *Am J Med* 1999;106:378-379.

Mark Andrew Hlatky, MD/Page 30

122. Hlatky MA. Role of economic models in randomized clinical trials. *Am Heart J* 1999;137:S41-S46.
123. Heidenreich PA, McDonald KM, Hastie T, Fadel B, Hagan V, Lee BK, Hlatky MA. Meta-analysis of trials comparing beta-blockers, calcium antagonists and nitrates for stable angina. *JAMA* 1999;281:1927-1936.
124. Hornberger J, Bloch DA, Hlatky MA, Baumgartner W. Patient preferences in coronary revascularization. *Am Heart J* 1999;137:1153-1162.
125. Hlatky MA, Boothroyd DB, Brooks MM, Rosen A, Rogers WJ, Reeder GS, Smith HC, Ryan TJ, Pitt B, Whitlow PL, Wiens RD, Mark DB. Clinical correlates of the initial and long-term cost of coronary bypass surgery and coronary angioplasty. *Am Heart J* 1999;138:376-383.
126. Larson MS, McDonald K, Young C, Sung R, Hlatky MA. Quality of life before and after radiofrequency catheter ablation in patients with drug refractory atrioventricular nodal reentrant tachycardia. *Am J Cardiol* 1999;84:471-473.
127. Lin A, Lenert LA, Hlatky MA, McDonald KM, Olshen RA, Hornberger J. Clustering and the design of preference-assessment surveys in healthcare. *Health Serv Res* 1999;34:1033-1045.
128. Bourassa MG, Brooks MM, Mark DB, Trudel J, Detre KM, Pitt B, Reeder GS, Rogers WJ, Ryan TJ, Smith HC, Whitlow PL, Wiens RD, Hlatky MA. Quality of life after coronary revascularization in the United States and Canada. *Am J Cardiol* 2000;85:548-553.
129. Krumholz HM, Baker DW, Ashton CM, Dunbar SB, Friesinger GC, Havranek EP, Hlatky MA, Konstam M, Ordin DL, Pina IL, Pitt B, Spertus JA. Evaluating quality of care for patients with heart failure. *Circulation* 2000;101:e122-e140.
130. Quality of Care and Outcomes Research in CVD and Stroke Working Groups. Measuring and improving quality of care. A report from the American Heart Association/American College of Cardiology First Scientific Forum on Assessment of Healthcare Quality in Cardiovascular Disease and Stroke. *Circulation* 2000;101:1483-1493.
131. The BARI Investigators (Writing Committee: Alderman EL, Brooks MM, Bourassa M, Califf RM, Chaitman BR, Detre K, Faxon D, Frye R, Hardison RM, Hlatky M, Holubkov R, Jones RH, Kelsey SF, Schaff H, Shemin RJ, Sopko G, Sutton-Tyrrell K, Williams DO). Seven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic status. *J Am Coll Cardiol* 2000;35:1122-1129.
132. Hlatky MA. Should we measure health-related quality of life? *Am Heart J* 2000;140:359-360.
133. Yock CA, Boothroyd DB, Owens DK, Winston C, Hlatky MA. Projected long-term costs of coronary stenting in multivessel coronary disease based on the experience of the Bypass Angioplasty Revascularization Investigation (BARI). *Am Heart J* 2000;140:556-564.

Mark Andrew Hlatky, MD/Page 31

134. Fu Y, Chang WC, Mark D, Califf RM, Mackenzie B, Granger CB, Topol EJ, Hlatky M, Armstrong PW. Canadian-American differences in the management of acute coronary syndromes in the GUSTO IIb trial. One-year follow-up of patients without ST-segment elevation. *Circulation* 2000;102:1375-1381.
135. Cheng CHF, Sanders GD, Hlatky MA, Heidenreich P, McDonald KM, Lee BK, Larson MS, Owens DK. Cost-effectiveness of radiofrequency ablation for supraventricular tachycardia. *Ann Intern Med* 2000;133:864-876.
136. Hlatky MA. Quality of life in octogenarians with heart disease. *Am J Geriatr Cardiol* 2000;9 (Suppl):83-85, 96.
137. McDonald KM, Hlatky MA. Cost reduction and implantable cardioverter defibrillator implantation. *J Cardiovasc Electrophysiol* 2001;12:167-168.
138. Hassan SA, Hlatky MA, Boothroyd DB, Winston C, Mark DB, Brooks MM, Eagle KA. Outcomes of noncardiac surgery after coronary bypass surgery or coronary angioplasty in the Bypass Angioplasty Revascularization Investigation (BARI). *Am J Med* 2001;110:260-266.
139. Shlipak MG, Elmouchi DA, Herrington DM, Lin F, Grady D, Hlatky MA. The incidence of unrecognized myocardial infarction in women with coronary heart disease. *Ann Intern Med* 2001;134:1043-1047.
140. Hlatky MA, Bigger T. Cost-effectiveness of the implantable cardioverter defibrillator? *Lancet* 2001;357:1817-1818.
141. Heidenreich PA, Alloggiamento T, Melsop K, McDonald KM, Go AS, Hlatky MA. The prognostic value of troponin in patients with non-ST elevation acute coronary syndromes: A meta-analysis. *J Am Coll Cardiol* 2001;38:478-485.
142. Hlatky MA, Dudley RA. Operator volume and clinical outcomes of primary coronary angioplasty for patients with acute myocardial infarction. *Circulation* 2001;104:2155-2157.
143. Sanders GD, Hlatky MA, Every NR, McDonald KM, Heidenreich PA, Parsons LS, Owens DK. Potential cost effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction. *Ann Intern Med* 2001;135:870-883.
144. Weiss JP, Parsons LS, Every NR, Weaver WD, Hlatky MA. Does enrollment in a randomized clinical trial lead to higher cost of routine care? *Am Heart J* 2002;143:140-144.
145. Hlatky MA, Boothroyd D, Vittinghoff E, Sharp P, Whooley MA. Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy. Results from the Heart and Estrogen/Progestin Replacement Study (HERS) Trial. *JAMA* 2002;287:591-597.
146. Barnett PG, Chen S, Boden WE, Chow B, Every NR, Lavori PW, Hlatky MA. Cost-effectiveness of a conservative, ischemia-guided management strategy after non-Q-wave myocardial infarction: Results of a randomized trial. *Circulation* 2002;105:680-684.

Mark Andrew Hlatky, MD/Page 32

147. Weiss JP, Saynina O, McDonald KM, McClellan MB, Hlatky MA. Effectiveness and cost-effectiveness of implantable cardioverter defibrillators in the treatment of ventricular arrhythmias among Medicare beneficiaries. *Am J Med* 2002;112:519-527.
148. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, Hsia J, Hulley S, Herd A, Khan S, Newby LK, Waters D, Vittinghoff E, Wenger N. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/progestin Replacement Study follow-up (HERS II). *JAMA* 2002;288:49-57.
149. Hlatky MA. Economic endpoints in clinical trials. *Epidemiol Rev* 2002;24:80-84.
150. Mark DB, Hlatky MA. Medical economics and the assessment of value in cardiovascular medicine: Part I. *Circulation* 2002;106:516-520.
151. Mark DB, Hlatky MA. Medical economics and the assessment of value in cardiovascular medicine. Part II. *Circulation* 2002;106:626-630.
152. Every N, Hallstrom A, McDonald KM, Parsons L, Thom D, Weaver D, Hlatky MA. Risk of sudden versus nonsudden cardiac death in patients with coronary artery disease. *Am Heart J* 2002;144:390-396.
153. Hlatky MA, Saynina O, McDonald KM, Garber AM, McClellan MB. Utilization and outcomes of the implantable cardioverter defibrillator, 1987-1995. *Am Heart J* 2002;144:397-403.
154. Hsu J, Uratsu C, Truman A, Quesenberry C, McDonald KM, Hlatky MA, Selby J. Life after a ventricular arrhythmia. *Am Heart J* 2002;144:404-412.
155. McDonald KM, Hlatky MA, Saynina O, Geppert J, Garber AM, McClellan MB. Trends in hospital treatment of ventricular arrhythmias among Medicare beneficiaries, 1985-1995. *Am Heart J* 2002;144:413-421.
156. Heidenreich PA, Keeffe B, McDonald KM, Hlatky MA. Overview of randomized trials of antiarrhythmic drugs and devices for the prevention of sudden cardiac death. *Am Heart J* 2002; 144:422-430.
157. Alexander M, Baker L, Clark C, McDonald KM, Rowell R, Saynina O, Hlatky MA. Management of ventricular arrhythmias in diverse populations in California. *Am Heart J* 2002; 144:431-439.
158. Owens DK, Sanders GD, Heidenreich PA, McDonald KM, Hlatky MA. Effect of risk stratification on the cost effectiveness of the implantable cardioverter defibrillator. *Am Heart J* 2002;144:440-448.
159. Hlatky MA, Boothroyd DB, Johnstone IM. Economic evaluation in long-term clinical trials. *Stat Med* 2002;21:2879-2888.
160. Gregoratos G, Abrams J, Epstein AE, Freedman RA, Hayes DL, Hlatky MA, Kerber RE, Naccarelli GV, Schoenfeld MH, Silka MJ, Winters SL. ACC/AHA/NASPE 2002 guideline update

Mark Andrew Hlatky, MD/Page 33

- for implantation of cardiac pacemakers and antiarrhythmia devices: Summary article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). *Circulation* 2002;106:2145-2161. (Published concurrently in *J Am Coll Cardiol* 2002;40:1703-1719, and *J Cardiovasc Electrophysiol* 2002;13:1183-1199).
161. Melsop KA, Boothroyd DB, Hlatky MA. Quality of life and utility in patients with coronary artery disease. *Am Heart J* 2003;145:36-41.
 162. Khan MA, Hlatky MA, Liu MW, Lin F, Rogers WJ, Shlipak MG. Effect of postmenopausal hormone therapy on coronary heart disease events after percutaneous transluminal coronary angioplasty. *Am J Cardiol* 2003;91:989-991
 163. Rumsfeld JS, Magid DJ, Plomondon ME, Sacks J, Henderson W, Hlatky M, Sethi G, Morrison DA. Health-related quality of life after percutaneous coronary intervention versus coronary bypass surgery in high risk patients with medically refractory ischemia. *J Am Coll Cardiol* 2003;41:1732-1738.
 164. Ruo B, Rumsfeld JS, Hlatky MA, Liu H, Browner WS, Whooley MA. Depressive symptoms and health-related quality of life. The Heart and Soul Study. *JAMA* 2003;290:215-221.
 165. Jha AK, Varosy PD, Kanaya AM, Hunninghake DB, Hlatky MA, Waters DD, Furberg CD, Shlipak MG. Differences in medical care and disease outcomes among black and white women with heart disease. *Circulation* 2003;108:1089-1094.
 166. Yock CA, Boothroyd DB, Owens DK, Garber AM, Hlatky MA. Cost-effectiveness of bypass surgery versus stenting in patients with multivessel coronary artery disease. *Am J Med* 2003;115:382-389.
 167. Hlatky MA. Comorbidity and outcome in patients with coronary artery disease. *J Am Coll Cardiol* 2004;43:583-584.
 168. Shaw LJ, Lewis JF, Hlatky MA, Hsueh WA, Kelsey SF, Klein R, Manolio TA, Sharrett AR, Tracy RP. Women's ischemic syndrome evaluation: Current status and future research directions: report of the National heart, Lung and Blood Institute workshop: October 2-4, 2002: Section 5: gender-related risk factors for ischemic heart disease. *Circulation* 2004;109:e56-e58.
 169. Hlatky M, Go AS. Economic implications of transesophageal echocardiography guided cardioversion of atrial fibrillation. *J Am Coll Cardiol* 2004;43:1225-1227.
 170. Kurella M, Ireland C, Hlatky MA, Shlipak MG, Yaffe K, Hulley SB, Chertow GM. Physical and sexual function in women with chronic kidney disease. *Am J Kidney* 2004;43:868-876.
 171. Hlatky MA. Evidence-based use of cardiac procedures and devices. *N Engl J Med* 2004;350:2126-2128.

Mark Andrew Hlatky, MD/Page 34

172. Beckerman J, Wang P, Hlatky M. Cardiovascular screening of athletes. *Clin J Sports Med* 2004;14:127-133.
173. Hlatky MA. Coronary revascularization and quality of life. *Am Heart J* 2004;48:5-6.
174. Hlatky MA. Underuse of evidence-based therapies. *Circulation* 2004;110:644-645.
175. Hlatky MA, Massie BM. Cardiac resynchronization for heart failure. *Ann Intern Med* 2004;141:409-410.
176. Hlatky MA, Boothroyd DB, Melsop KA, Brooks MM, Mark DB, Pitt B, Reeder GS, Rogers WJ, Ryan TJ, Whitlow PL, Wiens RD. Medical costs and quality of life 10 to 12 years after randomization to angioplasty or bypass surgery for multivessel coronary artery disease. *Circulation* 2004;110:1960-1966.
177. Reynolds MW, Frame D, Scheye R, Rose ME, George S, Watson JB, Hlatky MA. A systematic review of the economic burden of chronic angina. *Am J Manag Care* 2004;10:S347-S357.
178. Shafazand S, Goldstein MK, Doyle RL, Hlatky MA, Gould MK. Health-related quality of life in patients with pulmonary arterial hypertension. *Chest* 2004;126:1452-1459.
179. Hlatky MA, Sanders GD, Owens DK. Evidence-based medicine and policy: The case of the implantable cardioverter defibrillator. *Health Aff (Millwood)* 2005 Jan-Feb;24(1)42-51.
180. Reed SD, Anstrom KJ, Bakhai A, Briggs AH, Califf RM, Cohen DJ, Drummond MF, Glick HA, Gnanasakthy A, Hlatky MA, O'Brien BJ, Torti FM, Tsiatis AA, Willan AR, Mark DB, Schulman KA. Conducting economic evaluations alongside multinational clinical trials: Toward a research consensus. *Am Heart J* 2005;149:434-443.
181. Sanders GD, Hlatky MA, Owens DK. Cost effectiveness of implantable cardioverter-defibrillators. *N Engl J Med* 2005;353:1471-1480.
182. Bonow RO, Bennett S, Casey DE, Ganiats TG, Hlatky MA, Konstam MA, Lambrew CT, Normand SL, Pina IL, Radford MJ, Smith AL, Stevenson LW. ACC/AHA clinical performance measures for adults with chronic heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Heart Failure Clinical Performance Measures). *Circulation* 2005;112:1853-1887. (published simultaneously in *J Am Coll Cardiol* 2005;46:1144-1178).
183. Hlatky MA. Cost effectiveness of cardiac resynchronization therapy. *J Am Coll Cardiol* 2005;46:2322-2324.
184. Go AS, Iribarren C, Chandra M, Lathon PV, Fortmann SP, Quertermous T, Hlatky MA. Statin and beta-blocker therapy and the initial presentation of coronary heart disease. *Ann Intern Med* 2006;144:229-238.

Mark Andrew Hlatky, MD/Page 35

185. Hlatky MA, Wang P. Improvement in quality of life after radiofrequency ablation. *Pacing Clin Electrophysiol* 2006;29:341-342.
186. Hlatky M, Heidenreich P. The value of BNP testing. *Arch Intern Med* 2006;166:1063-1064.
187. Hlatky MA, Melsop KA, Boothroyd DB. Economic evaluation of alternative strategies to treat patients with diabetes and coronary artery disease. *Am J Cardiol* 2006;97(Suppl):59G-65G.
188. Taylor-Piliae RE, Norton LC, Haskell WL, Mahbouda MH, Fair JM, Iribarren C, Hlatky MA, Go AS, Fortmann SP. Validation of a new brief physical activity survey among men and women aged 60-69 years. *Am J Epidemiol* 2006;164:598-606.
189. Stroupe KT, Morrison DA, Hlatky MA, Barnett PG, Cao L, Lyttle C, Hynes DM, Henderson WG. Cost-effectiveness of coronary artery bypass grafts versus percutaneous coronary intervention for revascularization of high-risk patients. *Circulation* 2006;114:1251-1257.
190. Ruo B, Bertenthal D, Sen S, Bittner V, Ireland CC, Hlatky MA. Self-rated health among women with coronary disease: Depression is as important as recent cardiovascular events. *Am Heart J* 2006;152:921.e1-921.e7.
191. Iribarren C, Go AS, Husson G, Sidney S, Fair JM, Quertermous T, Hlatky MA, Fortmann SP. Metabolic syndrome and early-onset coronary artery disease: Is the whole greater than its parts? *J Am Coll Cardiol* 2006;48:1800-1807.
192. Hlatky MA, Owens DK, Sanders GD. Cost-effectiveness as an outcome in randomized clinical trials. *Clin Trials* 2006;3:543-551.
193. Hlatky MA, Mark DB. The high cost of implantable defibrillators. *Eur Heart J* 2007;28:388-391.
194. The BARI Investigators (Writing Committee: Brooks MM, Alderman EL, Bates E, Bourassa M, Califf RM, Chaitman BR, Detre KM, Feit F, Frye RL, Gibbons RJ, Hardison RM, Hlatky MA, Holmes DR, Jacobs AK, Kelsey SF, Krauland M, Rogers WJ, Schaff HV, Schwartz L, Sutton-Tyrrell, K, Williams DO, Whitlow PL). The final ten-year follow-up results from the BARI randomized trial. *J Am Coll Cardiol* 2007;49:1600-1606.
195. Iribarren C, Husson G, Go AS, Lo JC, Fair JM, Rubin GD, Hlatky MA, Fortmann SP. Plasma leptin levels and coronary artery calcification in older adults. *J Clin Endocrinol Metab* 2007;92:729-732.
196. Al-Khatib SM, Sanders GD, Bigger JT, Buxton AE, Califf RM, Carlson M, Curtis A, Curtis J, Fain E, Gersh BJ, Gold MR, Haghighi-Mood A, Hammill SC, Healey J, Hlatky M, Hohnloser S, Kim RJ, Lee K, Mark D, Mianulli M, Mitchell B, Prystowsky EN, Smith J, Steinhaus D, Zareba W. Preventing tomorrow's sudden cardiac death today: Part I: Current data on risk stratification for sudden cardiac death. *Am Heart J* 2007;153:941-950.
197. Sanders GD, Al-Khatib SM, Berliner E, Bigger JT, Buxton AE, Califf RM, Carlson M, Curtis AB, Curtis JP, Domanski M, Fain E, Gersh BJ, Gold MR, Goldberger J, Haghighi-Mood A,

Mark Andrew Hlatky, MD/Page 36

- Hammill SC, Harder J, Healey J, Hlatky MA, Hohnloser SH, Lee KL, Mark DB, Mitchell B, Phurrough S, Prystowsky E, Smith JM, Stockbridge N, Temple R. Preventing tomorrow's sudden cardiac death today: Part II: Translating sudden cardiac death risk assessment strategies into practice and policy. *Am Heart J* 2007;153:951-959.
198. McAlister FA, Ezekowitz J, Hooton N, Vandermeer B, Spooner C, Dryden DM, Page RL, Hlatky MA, Rowe BH. Cardiac resynchronization therapy for patients with left ventricular systolic dysfunction: A systematic review. *JAMA* 2007;297:2502-2514.
199. Taylor-Piliae RE, Haskell WL, Iribarren C, Norton LC, Mahbouda MH, Fair JM, Hlatky MA, Go AS, Fortmann SP. Clinical utility of the Stanford Brief Activity Survey in men and women with early-onset coronary artery disease. *J Cardiopulm Prev Rehabil* 2007;27:227-232.
200. Fair JM, Kiazand A, Varady A, Mahbouba M, Norton L, Rubin GD, Iribarren C, Go AS, Hlatky MA, Fortmann SP. Ethnic differences in coronary artery calcium in a healthy cohort aged 60 to 69 years. *Am J Cardiol* 2007;100:981-985.
201. Ardigo D, Assimes TL, Fortmann SP, Go AS, Hlatky M, Hytopoulos E, Iribarren C, Tsao PS, Tabibiazar R, Quertermous T. Circulating chemokines accurately identify subjects with clinically significant atherosclerotic heart disease. *Physiol Genomics* 2007;31:402-409.
202. Bravata DM, Gienger AL, McDonald KM, Sundaram V, Perez MV, Varghese R, Kapoor JR, Ardehali R, Owens DK, Hlatky MA. Systematic review: The comparative effectiveness of percutaneous coronary interventions and coronary artery bypass surgery. *Ann Intern Med* 2007;147:703-716.
203. Hlatky MA, Quertermous T, Boothroyd DB, Priest JR, Glassford AJ, Myers RM, Fortmann SP, Iribarren C, Tabor HK, Assimes TL, Tibshirani RJ, Go AS. Polymorphisms in hypoxia inducible factor 1 and the initial clinical presentation of coronary disease. *Am Heart J* 2007;154:1035-1042.
204. Hlatky MA, Ashley E, Quertermous T, Boothroyd DB, Ridker P, Southwick A, Myers RM, Iribarren C, Fortmann SP, Go AS. Matrix metalloproteinase circulating levels, genetic polymorphisms, and susceptibility to acute myocardial infarction among patients with coronary artery disease. *Am Heart J* 2007;154:1043-1051.
205. Knowles JW, Wang H, Itakura H, Southwick A, Myers RM, Iribarren C, Fortmann SP, Go AS, Quertermous T, Hlatky MA. Association of polymorphisms in platelet and hemostasis system genes with acute myocardial infarction. *Am Heart J* 2007;154:1052-1058.
206. Itakura H, Sobel BE, Boothroyd D, Leung LL, Iribarren C, Go AS, Fortmann SP, Quertermous T, Hlatky MA. Do plasma biomarkers of coagulation and fibrinolysis differ between patients who have experienced an acute myocardial infarction versus stable exertional angina? *Am Heart J* 2007;154:1059-1064.
207. Assimes TL, Knowles JW, Priest JR, Basu A, Borchert A, Volcik KA, Grove ML, Tabor HK, Southwick A, Tabibiazar R, Sidney S, Boerwinkle E, Go AS, Iribarren C, Hlatky MA, Fortmann SP, Myers RM, Kuhn H, Risch N, Quertermous T. A near null variant of 12/15-LOX encoded by

Mark Andrew Hlatky, MD/Page 37

- a novel SNP in *ALOX15* and the risk of coronary artery disease. *Atherosclerosis* 2008;198:136-144.
208. Burt JR, Iribarren C, Fair JM, Norton LC, Mahboubia M, Rubin GD, Hlatky MA, Go AS, Fortmann SP. Incidental findings on cardiac multidetector row computed tomography among healthy older adults: Prevalence and clinical correlates. *Arch Intern Med* 2008;168:756-761.
209. Assimes TL, Knowles JW, Priest JR, Basu A, Volcik KA, Southwick A, Tabor HK, Hartiala J, Allayee H, Grove ML, Tabibiazar R, Sidney S, Fortmann SP, Go A, Hlatky M, Iribarren C, Boerwinkle E, Myers R, Risch N, Quertermous T. Common polymorphisms of *ALOX5* and *ALOX5AP* and risk of coronary artery disease. *Hum Genet* 2008;124:399-408.
210. Knowles JW, Assimes TL, Boerwinkle E, Fortmann SP, Go A, Grove ML, Hlatky M, Iribarren C, Li J, Myers R, Risch N, Sidney S, Southwick A, Volcik KA, Quertermous T. Failure to replicate an association of SNPs in the oxidized LDL receptor gene (*OLR1*) with CAD. *BMC Med Genet* 2008;9:23.
211. Epstein AE, DiMarco JP, Ellenbogen KA, Estes M, Freedman RA, Gettes LS, Gillinov M, Gregoratos G, Hammill SC, Hayes DL, Hlatky MA, Newby LK, Page RL, Schoenfeld MH, Silka MJ, Stevenson LW, Sweeney MO. ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 2008;51:2085-2105. (Published simultaneously in *Circulation* 2008;117:2820-2840 and *Heart Rhythm* 2008;5:934-955.)
212. Assimes TL, Knowles JW, Basu A, Iribarren C, Southwick A, Tang H, Absher D, Li J, Fair JM, Rubin GD, Sidney S, Fortmann SP, Go AS, Hlatky MA, Myers RM, Risch N, Quertermous T. Susceptibility locus for clinical and subclinical coronary artery disease at chromosome 9p21 in the multi-ethnic ADVANCE study. *Hum Mol Genet* 2008;17:2320-2328.
213. Hlatky MA, Bravata DM. Stents or surgery? New data on the comparative outcomes of percutaneous coronary intervention and coronary artery bypass graft surgery. *Circulation* 2008;118:325-327.
214. Chan KE, Lafayette RA, Whittemore AS, Hlatky MA, Moran J. Facility factors dominate the ability to achieve target hemoglobin levels in hemodialysis patients. *Nephrol Dial Transplant* 2008;23:2948-2956.
215. The BARI 2D Investigators (Writing Committee: Brooks MM, Barsness G, Chaitman B, Chung SC, Faxon D, Feit F, Frye R, Genuth S, Green J, Hlatky M, Kelsey S, Kennedy F, Krone R, Nesto R, Orchard T, O'Rourke R, Rihal C, Tardif JC). Baseline characteristics of patients with diabetes and coronary artery disease enrolled in the BARI 2D trial. *Am Heart J* 2008;156:528-536.
216. Covinsky KE, Lin F, Bittner V, Hlatky MA, Knight SJ, Vittinghoff E. Health-related quality of life following coronary artery bypass graft surgery in post-menopausal women. *J Gen Intern Med* 2008;23:1429-1434.

Mark Andrew Hlatky, MD/Page 38

217. Kapoor JR, Gienger AL, Ardehali R, Varghese R, Perez MV, Sundaram V, McDonald KM, Owens DK, Hlatky MA, Bravata DM. Isolated disease of the proximal left anterior descending artery: Comparing the effectiveness of percutaneous coronary interventions and coronary artery bypass surgery. *J Am Coll Cardiol Intv* 2008;1:483-491.
218. Iribarren C, Hlatky MA, Chandra M, Fair JM, Rubin GD, Go AS, Burt JR, Fortmann SP. Incidental pulmonary nodules on cardiac computed tomography: Prognosis and use. *Am J Med* 2008;121:989-996.
219. Hlatky MA. Expanding the orbit of primary prevention B Moving beyond JUPITER. *N Engl J Med* 2008;359:2280-2282.
220. Heart Protection Study Collaborative Group (Writing Committee: Mihaylova B, Briggs A, Hlatky M, Armitage J, Parish S, Gray A, Collins R). Statin cost-effectiveness in the United States for people at different vascular risk levels. *Circ Cardiovasc Qual Outcomes* 2009;2:65-72.
221. Hlatky MA, Boothroyd DB, Bravata DM, Boersma E, Booth J, Brooks MM, Carrié D, Clayton TC, Danchin N, Flather M, Hamm CW, Hueb WA, Kahler J, Kelsey SF, King SB, Kosinski AS, Lopes N, McDonald KM, Rodriguez A, Serruys P, Sigwart U, Stables RH, Owens DK, Pocock SJ. Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: A collaborative analysis of individual patient data from ten randomised trials. *Lancet* 2009;373:1190-1197.
222. Hlatky MA, Heidenreich PA. The year in epidemiology, health services research, and outcomes research. *J Am Coll Cardiol* 2009;53:1459-1466.
223. Lee KK, Fortmann SP, Fair JM, Iribarren C, Rubin GD, Varady A, Go AS, Quertermous T, Hlatky MA. Insulin resistance independently predicts the progression of coronary artery calcification. *Am Heart J* 2009;157:939-945.
224. Hlatky MA. Evaluating use of coronary computed tomography angiography in the emergency department. *J Am Coll Cardiol* 2009;53:1651-1652.
225. Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH, Elkind MSV, Go AS, Harrell FE, Howard BV, Howard VJ, Hsue PY, Kramer CM, McConnell JP, Normand SLT, O'Donnell CJ, Smith SC, Wilson PWF. Criteria for evaluation of novel markers of cardiovascular risk. A Scientific Statement from the American Heart Association. *Circulation* 2009;119:2408-2416.
226. Melsop K, Brooks MM, Boothroyd DB, Hlatky MA. Effect of race in the clinical outcomes in the Bypass Angioplasty Revascularization Investigation trial. *Circ Cardiovasc Qual Outcomes* 2009;2:186-190.
227. Chan K, Moran J, Hlatky M, Lafayette R. Protocol adherence and the ability to achieve target haemoglobin levels in haemodialysis patients. *Nephrol Dial Transplant* 2009;24:1956-1962.
228. BARI 2D Study Group (Writing Committee: Frye RL, August P, Brooks MM, Chaitman BR, Genuth SM, Goldberg SH, Hardison RM, Hlatky MA, Jones TLZ, Kelsey SF, MacGregor JM,

Mark Andrew Hlatky, MD/Page 39

- Molitch ME, Nesto RW, Orchard TJ, Sako EY, Sobel BE). A randomized trial of therapies for type 2 diabetes and coronary artery disease. *N Engl J Med* 2009;360:2503-2515.
229. Garber AM, Hlatky MA. The confirmatory trial in comparative effectiveness research. *N Engl J Med* 2009;361:1498-1499.
230. Hlatky MA, Iribarren C. The dilemma of incidental findings on cardiac computed tomography. *J Am Coll Cardiol* 2009;54:1542-1543.
231. Peterson ED, Spertus JA, Cohen DJ, Hlatky MA, Go AS, Vickrey BG, Saver JL, Hinton PC. Vision and creation of the American Heart Association Pharmaceutical Roundtable Outcomes Research Centers. *Circ Cardiovasc Qual Outcomes* 2009;2:663-670.
232. Hachamovitch R, Johnson JR, Hlatky MA, Cantagallo L, Johnson BH, Coughlan M, Hainer J, Gierbolini J, Di Carli MF. The study of myocardial perfusion and coronary anatomy imaging roles in CAD (SPARC): design, rationale, and baseline patient characteristics of a prospective, multicenter observational registry comparing PET, SPECT, and CTA for resource utilization and clinical outcomes. *J Nucl Cardiol* 2009;16:935-948.
233. Hlatky MA, Heidenreich P. The year in epidemiology, health services research and outcomes research. *J Am Coll Cardiol* 2009;54:2343-2351.
234. Hlatky MA, Boothroyd DB, Melsop KA, Kennedy L, Rihal C, Rogers WJ, Venkitachalam L, Brooks MM. Economic outcomes of treatment strategies for type 2 diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial. *Circulation* 2009;120:2550-2558.
235. Zakharia F, Basu A, Absher D, Assimes T, Fortmann S, Go A, Hlatky M, Iribarren C, Knowles J, Li J, Narasimhan B, Olshen R, Sidney S, Southwick A, Myers R, Quertermous T, Risch N, Tang H. Characterizing the admixed African ancestry of African Americans. *Genome Biol* 2009;10[12]:R141.
236. Dallongeville J, Iribarren C, Ferrières J, Lyon L, Evans A, Go AS, Arveiler D, Fortmann SP, Ducimetière P, Hlatky MA, Amouyel P, Southwick A, Quertermous T, Meirhaeghe A. Peroxisome proliferator-activated receptor gamma polymorphisms and coronary heart disease. *PPAR Res* 2009;2009:543746.
237. Taylor-Piliae RE, Fair JM, Haskell WL, Varady AN, Iribarren C, Hlatky MA, Go AS, Fortmann SP. Validation of the Stanford Brief Activity Survey: Examining psychological factors and physical activity levels in older adults. *J Phys Act Health* 2010;7:87-94.
238. Yock CA, Isbill JM, King SB, Hlatky MA. Repeat coronary revascularization procedures after successful bare-metal or drug-eluting stent implantation. *J Invasive Cardiol* 2010;22:27-33.
239. Sydow K, Fortmann SP, Fair JM, Varady A, Hlatky MA, Go AS, Iribarren C, Tsao PS. Distribution of asymmetric dimethylarginine among 980 healthy, older adults of different ethnicities. *Clin Chem* 2010;56:111-120.

Mark Andrew Hlatky, MD/Page 40

240. Hlatky MA, Chung SC, Escobedo J, Hillegass WB, Melsop K, Rogers W, Brooks MM. The effect of obesity on quality of life in patients with diabetes and coronary artery disease. *Am Heart J* 2010;159:292-300.
241. DeMaria AN, Bax JJ, Ben-Yehuda O, Feld GK, Greenberg BH, Hall J, Hlatky M, Lew WY, Lima JA, Maisel AS, Narayan SM, Nissen S, Sahn DJ, Tsimikas S. Highlights of the year in JACC 2009. *J Am Coll Cardiol* 2010;55:380-407.
242. Wheeler MT, Heidenreich PA, Froelicher VF, Hlatky MA, Ashley EA. Cost effectiveness of pre-participation screening for prevention of sudden cardiac death in young athletes. *Ann Intern Med* 2010;152:276-286.
243. Mark DB, Berman DS, Budoff MJ, Carr JJ, Gerber TC, Hecht HS, Hlatky MA, Hodgson JM, Lauer MS, Miller JM, Morin RL, Mukherjee D, Poon M, Rubin GD, Schwartz RS. ACCF/ACR/AHA/NASCI/SAIP/SCAI/SCCT 2010 expert consensus document on coronary computed tomography angiography. A report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. *Circulation* 2010;121:2509-2543 (published simultaneously in *J Am Coll Cardiol* 2010;55:2663-2699 and *Catheter Cardiovasc Interv* 2010;76:E1-E42).
244. Freeman JV, Wang Y, Curtis JP, Heidenreich PA, Hlatky MA. The relation between hospital procedure volume and complications of cardioverter-defibrillator implantation from the Implantable Cardioverter-Defibrillator Registry. *J Am Coll Cardiol* 2010;56:1133-1139.
245. Lee KK, Cipriano LE, Owens DK, Go AS, Hlatky MA. Cost-effectiveness of using high sensitivity C-reactive protein to identify intermediate and low cardiovascular risk individuals for statin therapy. *Circulation* 2010;122:1478-1487.
246. Brooks MM, Chung SC, Helmy T, Hillegass WB, Escobedo J, Melsop KA, Massaro EM, McBane RD, Hyde P, Hlatky MA. Health status after treatment for coronary artery disease and type 2 diabetes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial. *Circulation* 2010;122:1690-1699.
247. Assimes TL, Hólm H, Kathiresan S, Reilly MP, Thorleifsson G, Voight BF, Erdmann J, Willenborg C, Vaidya D, Xie C, Patterson CC, Morgan TM, Burnett MS, Li M, Hlatky MA, Knowles JW, Thompson JR, Absher D, Iribarren C, Go A, Fortmann SP, Sidney S, Risch N, Tang H, Myers RM, Berger K, Stoll M, Shah SH, Thorgeirsson G, Andersen K, Havulinna AS, Herrera JE, Faraday N, Kim Y, Kral BG, Mathias R, Ruczinski I, Suktitipat B, Wilson AF, Yanev LR, Becker LC, Linsel-Nitschke P, Lieb W, König IR, Hengstenberg C, Fischer M, Stark K, Reinhard W, Winogradow J, Grassl M, Grosshennig A, Preuss M, Schreiber S, Wichmann HE, Meisinger C, Yee J, Friedlander Y, Do R, Meigs JB, Williams G, Nathan DM, MacRae CA, Qu L, Wilensky RL, Matthaï WH, Qasim AN, Hakonarson H, Pichard AD, Kent KM, Satler L, Lindsay JM, Waksman R, Knouff CW, Waterworth DM, Walker MC, Mooser VE, Marrugat J, Lucas G, Subirana I, Sala J, Ramos R, Martinelli N, Olivieri O, Trabetti E, Malerba G, Pignatti PF, Guiducci C, Mirel D, Parkin M, Hirschhorn JN, Asselta R, Duga S, Musunuru K, Daly MJ, Purcell S, Eifert S, Braund PS, Wright BJ, Balmforth AJ, Ball SG, Myocardial Infarction Genetics Consortium, Wellcome Trust Case Control Consortium, Cardiogenics, Ouweland WH,

Mark Andrew Hlatky, MD/Page 41

- Deloukas P, Scholz M, Cambien F, Huge A, Scheffold T, Salomaa V, Girelli D, Granger CB, Peltonen L, McKeown PP, Altshuler D, Melander O, Devaney JM, Epstein SE, Rader DJ, Elosua R, Engert JC, Anand SS, Hall AS, Ziegler A, O'Donnell CJ, Spertus JA, Siscovick D, Schwartz SM, Becker D, Thorsteinsdottir U, Stefansson K, Schunkert H, Samani NJ, Quertermous T. Lack of association between the Trp719Arg polymorphism in kinesin-like protein 6 and coronary artery disease in 19 case-control studies. *J Am Coll Cardiol* 2010;56:1552-1563.
248. Abraham NS, Hlatky MA, Antman EM, Bhatt DL, Bjorkman DJ, Clark CB, Furberg CD, Johnson DA, Kahi CJ, Laine L, Mahaffey KW, Quigley EM, Scheiman J, Sperling LS, Tomaselli GF. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: A focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. *J Am Coll Cardiol* 2010;56:2051-2066 (published simultaneously in *Circulation* 2010;122: 2619-2633 and *Am J Gastroenterol* 2010;105:2533-2549.)
249. Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, Foster E, Hlatky MA, Hodgson JM, Kushner FG, Lauer MS, Shaw LJ, Smith SC, Taylor AJ, Weintraub WS, Wenger NK. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation* 2010;122:2748-2764, e584-e636 (published simultaneously in *J Am Coll Cardiol* 2010;56:2182-2199, e50-e103).
250. Terashima M, Nguyen PK, Rubin GD, Meyer CH, Shimakawa A, Nishimura DG, Ehara S, Iribarren C, Courtney BK, Go AS, Hlatky MA, Fortmann SP, McConnell MV. Right coronary wall MRI in the older asymptomatic ADVANCE cohort: Positive remodeling and associations with Type 2 diabetes and coronary calcium. *J Cardiovasc Magn Reson* 2010;12:75.
251. Perez MV, Kumarasamy NA, Owens DK, Wang PJ, Hlatky MA. Cost-effectiveness of genetic testing in family members of patients with long QT syndrome. *Circ Cardiovasc Qual Outcomes* 2011;4:76-84.
252. Demaria AN, Bax JJ, Ben-Yehuda O, Feld GK, Greenberg BH, Hall J, Hlatky M, Lew WY, Lima JA, Maisel AS, Narayan SM, Nissen S, Sahn DJ, Tsimikas S. Highlights of the year in JACC 2010. *J Am Coll Cardiol* 2011;57:480-514.
253. Hlatky M. The cost-effectiveness of rosuvastatin therapy: JUPITER (Justification for the Use of statins in Prevention: An Intervention Trial Evaluating Rosuvastatin). *J Am Coll Cardiol* 2011;57:792-793.
254. Liu V, Bhattacharya J, Weill D, Hlatky MA. Persistent racial disparities in survival after heart transplantation. *Circulation* 2011;123:1642-1649.
255. Hlatky MA. What can we learn from a decision model? *Arch Intern Med* 2011;171:667-668.
256. Hlatky MA, Heidenreich P. The year in epidemiology, health services research and outcomes research. *J Am Coll Cardiol* 2011;57:1859-1866.

Mark Andrew Hlatky, MD/Page 42

257. Taylor-Piliae RE, Fair JM, Varady AN, Hlatky MA, Norton LC, Iribarren C, Go AS, Fortmann SP. Ankle brachial index screening in asymptomatic older adults. *Am Heart J* 2011;161:979-985.
258. Kaltman JR, Thompson PD, Lantos J, Berul CI, Botkin J, Cohen JT, Cook NR, Corrado D, Drezner J, Frick KD, Goldman S, Hlatky M, Kannankeril PJ, Leslie L, Priori S, Saul JP, Shapiro-Mendoza CK, Siscovick D, Vetter VL, Boineau R, Burns KM, Friedman RA. Screening for sudden cardiac death in the young. Report from a National Heart, Lung and Blood Institute Working Group. *Circulation* 2011;123:1911-1918.
259. Nguyen PK, Terashima M, Fair JM, Varady A, Taylor-Piliae RE, Iribarren C, Go AS, Haskell WL, Hlatky MA, Fortmann SP, McConnell MV. Physical activity in older subjects is associated with increased coronary vasodilation. The ADVANCE Study. *JACC Cardiovasc Imaging* 2011;4:622-629.
260. Janssens ACJW, Ioannidis JPA, Bedrosian S, Boffetta P, Dolan SM, Dowling N, Fortier I, Freedman AN, Grimshaw JM, Gulcher J, Gwinn M, Hlatky MA, Janes H, Kraft P, Melillo S, O'Donnell CJ, Pencina MJ, Ransohoff D, Schully SD, Seminara D, Winn DM, Wright CF, van Duijn CM, Little J, Khoury MJ. Strengthening the reporting of genetic risk prediction studies (GRIPS): Explanation and elaboration. *J Clin Epidemiol* 2011;64:e1-e22 (published simultaneously in *Eur J Clin Invest* 2011;41:1010-1035, *Eur J Epidemiol* 2011;26:313-337, and *Eur J Hum Genet* 2011;19:494).
261. Chung SC, Hlatky MA, Stone RA, Rana JS, Escobedo J, Rogers WJ, Bromberger JT, Kelsey SF, Brooks MM. Body mass index and health status in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial (BARI 2D). *Am Heart J* 2011;162:184-192.
262. Estes NAM, Sacco RL, Al-Khatib SM, Ellinor PT, Bezanson J, Alonso A, Antzelevitch C, Brockman R, Chen PS, Chugh SS, Curtis AB, DiMarco JP, Ellenbogen KA, Epstein AE, Ezekowitz MD, Fayad P, Gage BF, Go AS, Hlatky MA, Hylek EM, Jerosch-Herold M, Konstam M, Lee R, Packer DL, Po SS, Prystowsky EN, Redline S, Rosenberg Y, Van Wagener DR, Wood K, Yue L, Benjamin EJ. American Heart Association Atrial Fibrillation Research Summit: A Conference Report from the American Heart Association. *Circulation* 2011; 124: 363-372.
263. Lee KK, Fortmann SP, Varady A, Fair JM, Go AS, Quertermous T, Hlatky MA, Iribarren C. Racial variation in lipoprotein-associated phospholipase A₂ in older adults. *BMC Cardiovasc Disord* 2011;11:38.
264. Chung SC, Hlatky MA, Faxon D, Ramanathan K, Adler D, Mooradian A, Rihal C, Stone RA, Bromberger JT, Kelsey SF, Brooks MM. The effect of age on clinical outcomes and health status: BARI 2D (Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes). *J Am Coll Cardiol* 2011;58:810-819.
265. Kessler DP, Kroch E, Hlatky MA. The effect of bivalirudin on costs and outcomes of treatment of ST-segment elevation myocardial infarction. *Am Heart J* 2011;162:494-500.

Mark Andrew Hlatky, MD/Page 43

266. Go AS, Bansal N, Chandra M, Lathon PV, Fortmann SP, Iribarren C, Hsu CY, Hlatky MA. Chronic kidney disease and risk of presenting with acute myocardial infarction versus stable exertional angina in adults with coronary artery disease. *J Am Coll Cardiol* 2011;58:1600-1607.
267. Bansal N, Hsu CY, Chandra M, Iribarren C, Fortmann SP, Hlatky MA, Go AS. Potential role of differential medication use in explaining excess risk of cardiovascular events and death associated with chronic kidney disease: A cohort study. *BMC Nephrol* 2011;12:44.
268. Hlatky MA, Shilane D, Boothroyd DB, Boersma E, Brooks MM, Carrié D, Clayton TC, Danchin N, Flather M, Hamm CW, Hueb WA, Kahler J, Lopes N, Pocock SJ, Rodriguez A, Serruys P, Sigwart U, Stables RH. The effect of internal thoracic artery grafts on long-term clinical outcomes after coronary bypass surgery. *J Thorac Cardiovasc Surg* 2011;142:829-835.
269. Shreibati JB, Baker LC, Hlatky MA. Association of coronary CT angiography or stress testing with subsequent utilization and spending among Medicare beneficiaries. *JAMA* 2011;306:2128-2136.
270. Shah RU, Freeman JV, Shilane D, Wang PJ, Go AS, Hlatky MA. Procedural complications, re-hospitalization, and repeat procedures after catheter ablation for atrial fibrillation. *J Am Coll Cardiol* 2012;59:143-149.
271. Freeman JV, Wang Y, Curtis JP, Heidenreich PA, Hlatky MA. Physician procedure volume and complications of cardioverter-defibrillator implantation. *Circulation* 2012;125:57-64.
272. Hachamovitch R, Nutter B, Hlatky MA, Shaw LJ, Ridner ML, Dorbala S, Beanlands RS, Chow BJ, Branscomb E, Chareonthaitawee P, Weigold WG, Voros S, Abbara S, Yasuda T, Jacobs JE, Lesser J, Berman DS, Thomson LE, Raman S, Heller GV, Schussheim A, Brunken R, Williams KA, Farkas S, Delbeke D, Schoepf UJ, Reichel N, Rabinowitz S, Sigman SR, Patterson R, Corn CR, White R, Kazerooni E, Corbett J, Bokhari S, Machac J, Guarneri E, Borges-Neto S, Millstine JW, Caldwell J, Arrighi J, Hoffmann U, Budoff M, Lima J, Johnson JR, Johnson B, Gaber M, Williams JA, Foster C, Hainer J, Di Carli MF. Patient management after noninvasive cardiac imaging: Results from SPARC (Study of myocardial perfusion and coronary anatomy imaging roles in coronary artery disease). *J Am Coll Cardiol* 2012;59:462-474.
273. Demaria AN, Bax JJ, Ben-Yehuda O, Feld GK, Greenberg BH, Hall J, Hlatky M, Lew WY, Lima JA, Maisel AS, Narayan SM, Nissen S, Sahn DJ, Tsimikas S. Highlights of the year in JACC 2011. *J Am Coll Cardiol* 2012;59:503-537.
274. Hlatky MA, Simons CT. Cost-effectiveness of transcatheter aortic valve replacement. *Circulation* 2012;125:1076-1077.
275. Hlatky M. Framework for evaluating novel risk markers. *Ann Intern Med* 2012;156:468-469.
276. Mudumbai SC, Wagner T, Mahajan S, King R, Heidenreich PA, Hlatky M, Wallace A, Mariano ER. Vascular surgery patients prescribed preoperative β -blockers experienced a decrease in the maximal heart rate observed during induction of general anesthesia. *J Cardiothorac Vasc Anesth* 2012;26:414-419.

Mark Andrew Hlatky, MD/Page 44

277. Kazi DS, Hlatky MA. Repeat revascularization is a faulty endpoint for clinical trials. *Circ Cardiovasc Qual Outcomes* 2012;5:249-250.
278. Hlatky MA, Douglas PS, Cook NL, Wells B, Benjamin EJ, Dickersin K, Goff DC, Hirsch AT, Hylek EM, Peterson ED, Roger VL, Selby JV, Udelson JE, Lauer MS. Future directions for cardiovascular disease comparative effectiveness research. Report of a workshop sponsored by the National Heart, Lung, and Blood Institute. *J Am Coll Cardiol* 2012;60:569-580.
279. Vieira RD, Hueb W, Hlatky M, Favarato D, Rezende PC, Garzillo CL, Lima EG, Soares PR, Hueb AC, Pereira AC, Ramires JAF, Filho RK. Cost-effectiveness analysis for surgical, angioplasty or medical therapeutics for coronary artery disease: 5-year follow-up of Medicine, Angioplasty or Surgery Study (MASS II) trial. *Circulation* 2012;126[suppl 1]:S145-S150.
280. Shreibati JB, Baker LC, Hlatky MA, Mell MW. Impact of the screening abdominal aortic aneurysms very efficiently (SAAAVE) act on abdominal ultrasound use among Medicare beneficiaries. *Arch Intern Med* 2012;172:1456-1462.
281. Goldstein BA, Arce CM, Hlatky MA, Turakhia M, Setoguchi S, Winkelmayr WC. Trends in the incidence of atrial fibrillation in older patients initiating dialysis in the United States. *Circulation* 2012;125:2293-2301.
282. Flather M, Rhee JW, Boothroyd DB, Boersma E, Brooks MM, Carrié D, Clayton TC, Danchin N, Hamm CW, Hueb WA, King SB, Pocock SJ, Rodriguez AE, Serruys P, Sigwart U, Stables RH, Hlatky MA. The effect of age on outcomes of coronary artery bypass surgery or percutaneous coronary intervention for multivessel coronary disease. A collaborative analysis of individual patient data from ten randomized trials. *J Am Coll Cardiol* 2012;60:2150-2157.
283. Chang TI, Shilane D, Kazi DS, Montez-Rath ME, Hlatky MA, Winkelmayr WC. Multivessel coronary artery bypass grafting versus percutaneous coronary intervention in ESRD. *J Am Soc Nephrol* 2012;23:2042-2049.
284. Hlatky MA. Compelling evidence for coronary-bypass surgery in patients with diabetes. *N Engl J Med* 2012;367:2437-2438.
285. Tavares LD, Barreto Neto J, Jardim JR, Souza GM, Hlatky MA, Nascimento OA. Cross-cultural adaptation and assessment of reproducibility of the Duke Activity Status Index for COPD patients in Brazil. *J Bras Pneumol* 2012;38:684-691.
286. Boothroyd DM, Mieres JJ, Grinfeld L, Fernández-Pereira C, Rodríguez-Granillo AM, Berrocal D, Palacios IP, O'Neill W, Hlatky M, Rodríguez AE. Comparative effectiveness at five years of drug-eluting stents, bare metal stents, and coronary bypass surgery: The ERACI III study. *Rev Argent Cardiol Interv* 2012;3:135-146.
287. Hlatky MA, Winkelmayr WC, Setoguchi S. Epidemiological and statistical methods for comparative effectiveness research. *Heart Fail Clin* 2013;9:29-36.

Mark Andrew Hlatky, MD/Page 45

288. Hlatky MA, Solomon MD, Shilane D, Leong TK, Brindis R, Go AS. Use of medications for secondary prevention after coronary bypass surgery compared with percutaneous coronary intervention. *J Am Coll Cardiol* 2013;61:295-301.
289. DeMaria AN, Bax JJ, Feld GK, Greenberg BH, Hall JL, Hlatky MA, Lew WYW, Lima JAC, Mahmud E, Maisel AS, Narayan SM, Nissen SE, Sahn DJ, Tsimikas S. Highlights of the year in *JACC* 2012. *J Am Coll Cardiol* 2013;61:357-385.
290. Epstein AE, Dimarco JP, Ellenbogen KA, Estes NA, Freedman RA, Gettes LS, Gillinov AM, Gregoratos G, Hammill SC, Hayes DL, Hlatky MA, Newby LK, Page RL, Schoenfeld MH, Silka MJ, Stevenson LW, Sweeney MO, Tracy CM, Epstein AE, Darbar D, Dimarco JP, Dunbar SB, Estes NA, Ferguson TB, Hammill SC, Karasik PE, Link MS, Marine JE, Schoenfeld MH, Shanker AJ, Silka MJ, Stevenson LW, Stevenson WG, Varosy PD, Anderson JL, Jacobs AK, Halperin JL, Albert NM, Creager MA, Demets D, Ettinger SM, Guyton RA, Hochman JS, Kushner FG, Ohman EM, Stevenson W, Yancy CW. 2012 ACCF/AHA/HRS Focused update incorporated into the ACCF/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. *Circulation* 2013;127:e283-e352. (Reprinted in *J Am Coll Cardiol* 2013;61:e6-e75, *J Thorac Cardiovasc Surg* 2012;144:e127-e145.)
291. Kazi DS, Hlatky MA. Atrial fibrillation ablation, symptoms, and stroke risk. *JAMA Intern Med* 2013;173:156-157.
292. Hlatky MA. Effectiveness is the key to cost-effectiveness. *Circulation* 2013;127:764-765.
293. Chan K, Patel RS, Newcombe P, Nelson CP, Qasim A, Epstein SE, Burnett S, Vaccarino VL, Zafari AM, Shah SH, Anderson JL, Carlquist JF, Hartiala J, Allayee H, Hinohara K, Lee BS, Erl A, Ellis KL, Goel A, Schaefer AS, El Mokhtari NE, Goldstein BA, Hlatky MA, Go AS, Shen GQ, Gong Y, Pepine C, Laxton RC, Whittaker JC, Tang WH, Johnson JA, Wang QK, Assimes TL, Nöthlings U, Farrall M, Watkins H, Richards AM, Cameron VA, Muendlein A, Drexel H, Koch W, Park JE, Kimura A, Shen WF, Simpson IA, Hazen SL, Horne BD, Hauser ER, Quyyumi AA, Reilly MP, Samani NJ, Ye S. Association between the chromosome 9p21 locus and angiographic coronary artery disease burden: A collaborative meta-analysis. *J Am Coll Cardiol* 2013;61:957-970.
294. Chang TI, Yang J, Freeman JV, Hlatky MA, Go AS. Effectiveness of β -blockers in heart failure with left ventricular systolic dysfunction and chronic kidney disease. *J Card Fail* 2013;19:176-182.
295. Hlatky MA. Volume, outcome and policy. *J Interv Card Electrophysiol* 2013;36:151-155.
296. Chang TI, Leong TK, Kazi DS, Lee HS, Hlatky MA, Go AS. Comparative effectiveness of coronary artery bypass grafting and percutaneous coronary intervention for multivessel coronary disease in a community-based population with chronic kidney disease. *Am Heart J* 2013;165:800-808.

Mark Andrew Hlatky, MD/Page 46

297. Hlatky MA, Boothroyd DB, Baker L, Kazi DS, Solomon MD, Chang TI, Shilane D, Go AS. Comparative effectiveness of multivessel coronary bypass surgery and multivessel percutaneous coronary intervention. A cohort study. *Ann Intern Med* 2013;158:727-734.
298. Simons CT, Cipriano LE, Shah RU, Garber AM, Owens DK, Hlatky MA. Transcatheter aortic valve replacement in nonsurgical candidates with severe, symptomatic aortic stenosis: A cost-effectiveness analysis. *Circ Cardiovasc Qual Outcomes* 2013;6:419-428.
299. Perez MV, Wang PJ, Larson JC, Soliman EZ, Limacher M, Rodriguez B, Klein L, Manson JE, Martin LW, Prineas R, Connelly S, Hlatky M, Wassertheil-Smoller S, Stefanick ML. Risk factors for atrial fibrillation and their population burden in postmenopausal women: The Women's Health Initiative Observational Study. *Heart* 2013;99:1173-1178.
300. Mell MW, Hlatky MA, Shreibati JB, Dalman RL, Baker LC. Late diagnosis of abdominal aortic aneurysms substantiates underutilization of abdominal aortic aneurysm screening for Medicare beneficiaries. *J Vasc Surg* 2013;57:1519-1523.
301. Hlatky MA, DeMaria AN. Does practice variation matter? *J Am Coll Cardiol* 2013;62:447-448.
302. Freeman JV, Yang J, Sung SH, Hlatky MA, Go AS. Effectiveness and safety of digoxin among contemporary adults with incident systolic heart failure. *Circ Cardiovasc Qual Outcomes* 2013;6:525-533.
303. Fearon WF, Shilane D, Pijls NHJ, Boothroyd DB, Tonino PAL, Barbato E, Juni P, De Bruyne B, Hlatky MA. Cost-effectiveness of percutaneous coronary intervention in patients with stable coronary disease and abnormal fractional flow reserve. *Circulation* 2013;128:1335-1340.
304. Crowson CS, Liao KP, Davis JM, Solomon DH, Matteson EL, Knutson KL, Hlatky MA, Gabriel SE. Rheumatoid arthritis and cardiovascular disease. *Am Heart J* 2013;166:622-628.
305. Lee KK, Shilane D, Hlatky MA, Yang J, Steimle AE, Go AS. Effectiveness and safety of spironolactone for systolic heart failure. *Am J Cardiol* 2013;112:1427-1432.
306. Ellrodt AG, Fonarow GC, Schwamm LH, Albert N, Bhatt DL, Cannon CP, Hernandez AF, Hlatky MA, Luepker RV, Peterson PN, Reeves M, Smith EE. Synthesizing lessons learned from Get With the Guidelines. The value of disease-based registries in improving quality and outcomes. *Circulation* 2013;128:2247-2260.
307. Hlatky MA, Saxena A, Koo BK, Erglis A, Zarins CK, Min JK. Projected costs and consequences of computed tomography-determined fractional flow reserve. *Clin Cardiol* 2013;36:743-748.
308. Hlatky MA, Shilane D, Chang TI, Boothroyd D, Go AS. Incremental prognostic information from kidney function in patients with new onset coronary heart disease. *Am Heart J* 2014;167:86-92.
309. Ioannidis JPA, Greenland S, Hlatky MA, Khoury MJ, Macleod MR, Moher D, Schulz KF, Tibshirani R. Increasing value and reducing waste in research design, conduct, and analysis. *Lancet* 2014;383:166-175.

Mark Andrew Hlatky, MD/Page 47

310. Hlatky MA, Ray RM, Burwen DR, Margolis KL, Johnson KC, Kucharska-Newton A, Manson JE, Robinson JG, Safford MM, Allison M, Assimes TL, Bavry AA, Berger J, Cooper-DeHoff RM, Heckbert SR, Li W, Liu S, Martin LW, Perez MV, Tindle HA, Winkelmayr WC, Stefanick ML. Use of Medicare data to identify coronary heart disease outcomes in the Women's Health Initiative (WHI). *Circ Cardiovasc Qual Outcomes* 2014;7:157-162.
311. Hlatky MA, Boothroyd D, Reitz B, Shilane D, Baker L, Go AS. Adoption and effectiveness of internal mammary artery grafting in coronary artery bypass surgery among Medicare beneficiaries. *J Am Coll Cardiol* 2014;63:33-39.
312. DeMaria AN, Adler ED, Bax JJ, Ben-Yehuda O, Feld GK, Greenberg BH, Hall JL, Hlatky MA, Lew WYW, Lima JAC, Mahmud E, Maisel AS, Narayan SM, Nissen SE, Sahn DJ, Tsimikas S. Highlights of the year in JACC 2013. *J Am Coll Cardiol* 2014;63:570-602.
313. Kazi DS, Garber AM, Shah RU, Dudley RA, Mell MW, Rhee C, Moshkevich S, Boothroyd DB, Owens DK, Hlatky MA. Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome. *Ann Intern Med* 2014;160:221-232.
314. Mark DB, Anderson JL, Brinker JA, Brophy JM, Casey DE, Cross RR, Edmundowicz D, Hachamovitch R, Hlatky MA, Jacobs JE, Jaskie S, Kett KG, Malhotra V, Masoudi FA, McConnell MV, Rubin GD, Shaw LJ, Sherman ME, Stanko S, Ward RP. ACC/AHA/ASE/ASNC/HRS/IAC/Mended Hearts/NASCI/RSNA/SAIP/SCAI/SCCT/SCMR/SNMMI 2014 health policy statement on use of noninvasive cardiovascular imaging: A report of the American College of Cardiology Foundation Clinical Quality Committee. *J Am Coll Cardiol* 2014;63:698-721.
315. Andersson C, Mérie C, Jørgensen M, Gislason GH, Torp-Pederson C, Overgaard C, Køber L, Jensen PF, Hlatky MA. Association of beta-blocker therapy on the risks of adverse cardiovascular events and deaths in patients with ischemic heart disease undergoing non-cardiac surgery: A Danish nationwide cohort study. *JAMA Intern Med* 2014;174:336-344.
316. Mell MW, Baker LC, Dalman RL, Hlatky MA. Gaps in preoperative surveillance and rupture of abdominal aortic aneurysms among Medicare beneficiaries. *J Vasc Surg* 2014;59:583-588.
317. Hlatky MA, Shilane D, Hachamovitch R, DiCarli MF. Economic outcomes in the study of myocardial perfusion and coronary anatomy imaging roles in coronary artery disease: The SPARC Registry. *J Am Coll Cardiol* 2014;63:1002-1008.
318. Hlatky MA. To test or not to test, that is the question. *Circ Cardiovasc Qual Outcomes* 2014;7:207-208.
319. Coutinho-Myrrha MA, Dias RC, Fernandes AA, Araújo CG, Hlatky MA, Pereira DG, Britto RR. Duke Activity Status Index for cardiovascular diseases: Validation of the Portuguese translation. *Arq Bras Cardiol* 2014;102:383-390.
320. Roth JA, Etzioni R, Waters TM, Pettinger M, Rossouw J, Anderson G, Chlebowski RT, Manson JE, Hlatky M, Johnson KC, Ramsey SD. Economic return from the Women's Health Initiative estrogen plus progestin clinical trial. *Ann Intern Med* 2014;160:594-602.

Mark Andrew Hlatky, MD/Page 48

321. Solomon MD, Go AS, Shilane D, Boothroyd D, Leong TK, Kazi DS, Chang TI, Hlatky MA. Comparative effectiveness of clopidogrel in medically managed patients with unstable angina and non-ST segment elevation myocardial infarction. *J Am Coll Cardiol* 2014;63:2249-2257.
322. Anderson JL, Heidenreich PA, Barnett PG, Creager MA, Fonarow GC, Gibbons RJ, Halperin JL, Hlatky MA, Jacobs AK, Mark DB, Masoudi FA, Peterson ED, Shaw LJ. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. *Circulation* 2014;129:2329-2245. (Published simultaneously in *J Am Coll Cardiol* 2014;63:2304-2322.)
323. Mudumbai SC, Wagner T, Mahajan S, King R, Heidenreich PA, Hlatky M, Wallace A, Mariano ER. Effectiveness of preoperative beta-blockade on intra-operative heart rate in vascular surgery cases conducted under regional or local anesthesia. *SpringerPlus* 2014;3:227.
324. Mell MW, Pettinger M, Proulx-Burns L, Heckbert SR, Allison MA, Criqui MH, Hlatky MA, Burwen DR. Evaluation of Medicare claims data to ascertain peripheral vascular events in the Women's Health Initiative. *J Vasc Surg* 2014;60:98-105.
325. Maron DJ, Hlatky MA. Trial to Assess Chelation Therapy (TACT) and equipoise. When evidence conflicts with beliefs. *Am Heart J* 2014;168:4-5.
326. Andersson C, Shilane D, Go AS, Chang TI, Kazi D, Solomon MD, Boothroyd DB, Hlatky MA. Beta-blocker therapy and cardiac events among patients with newly diagnosed coronary heart disease. *J Am Coll Cardiol* 2014;64:247-252.
327. Shreibati JB, Baker LC, McConnell MV, Hlatky MA. Outcomes after coronary artery calcium and other cardiovascular biomarker testing among asymptomatic Medicare beneficiaries. *Circ Cardiovasc Imaging* 2014;7:655-662.
328. Bavry AA, Thomas F, Allison M, Johnson KC, Howard BV, Hlatky M, Manson JE, Limacher MC. Nonsteroidal anti-inflammatory drugs and cardiovascular outcomes in women: Results from the Women's Health Initiative. *Circ Cardiovasc Qual Outcomes* 2014;7:603-610.
329. Kazi DS, Hlatky MA. Warfarin, genes, and the (health care) environment. *JAMA Intern Med* 2014;174:1338-1339.
330. Krishnaswami A, Leong TK, Hlatky MA, Chang TI, Go AS. Temporal trends in mortality after coronary artery revascularization in patients with end-stage renal disease. *Perm J* 2014;18:11-16.
331. Azarbal F, Stefanick ML, Salmoirago-Blotcher E, Manson JE, Albert CM, LaMonte MJ, Larson JC, Li W, Martin LW, Nassir R, Garcia L, Assimes TL, Tharp KM, Hlatky MA, Perez MV. Obesity, physical activity and their interaction in incident atrial fibrillation in post-menopausal women. *J Am Heart Assoc* 2014;3:e001127.
332. Chang TI, Leong TK, Boothroyd DB, Hlatky MA, Go AS. Acute kidney injury after CABG versus PCI: An observational study using 2 cohorts. *J Am Coll Cardiol* 2014;64:985-994.

Mark Andrew Hlatky, MD/Page 49

333. Hlatky MA. A long-term perspective on short-term outcomes. *J Am Coll Cardiol* 2014;64:2109-2110.
334. Andersson C, Gislason GH, Hlatky MA, Søndergaard KB, Pallisgaard J, Smith JG, Vasani RS, Larson MG, Jensen PF, Køber L, Torp-Pederson C. A risk score for predicting 30-day mortality in heart failure patients undergoing non-cardiac surgery. *Eur J Heart Fail* 2014;16:1310-1316.
335. Hlatky MA, Boothroyd DB, Baker LC, Go AS. Impact of drug-eluting stents on the comparative effectiveness of coronary artery bypass surgery and percutaneous coronary intervention. *Am Heart J* 2015;169:149-154.
336. Zhang Z, Kolm P, Grau-Sepulveda MV, Ponirakis A, O'Brien SM, Klein LW, Shaw RE, McKay C, Shahian DM, Grover FL, Mayer JE, Garratt KN, Hlatky M, Edwards FH, Weintraub WS. Cost-effectiveness of revascularization strategies. The ASCERT Study. *J Am Coll Cardiol* 2015;65:1-11.
337. Andersson C, Wissenberg M, Jørgensen ME, Hlatky MA, Mérie C, Jensen PF, Gislason GH, Køber L, Torp-Pedersen C. Age-specific performance of the revised cardiac risk index for predicting cardiovascular risk in elective noncardiac surgery. *Circ Cardiovasc Qual Outcomes* 2015;8:103-108.
338. Kimura T, Shiomi H, Kuribayashi S, Isshiki T, Kanazawa S, Ito H, Ikeda S, Forrest B, Zarins CK, Hlatky MA, Norgaard BL. Cost analysis of non-invasive fractional flow reserve derived from coronary computed tomographic angiography in Japan. *Cardiovasc Interv Ther* 2015;30:38-44.
339. Kazi DS, Hlatky MA. A delicate balance: The cost effectiveness of new antiplatelet agents. *J Am Coll Cardiol* 2015;65:477-479.
340. Shilane D, Hlatky MA, Winkelmayr WC, Chang TI. Coronary artery bypass graft type and outcomes in maintenance dialysis. *J Cardiovasc Surg (Torino)* 2015;56:463-471.
341. Kazi DS, Leong TK, Chang TI, Solomon MD, Hlatky MA, Go AS. Association of spontaneous bleeding and myocardial infarction with long-term mortality after percutaneous coronary intervention. *J Am Coll Cardiol* 2015;65:1411-1420.
342. Sanders GD, Owens DK, Hlatky MA. Potential cost-effectiveness of wearable cardioverter-defibrillator early post myocardial infarction. *J Innov Card Rhythm Manag* 2015;6:1929-1940.
343. Schmiegelow MD, Hedlin H, Stefanick ML, Mackey RH, Allison M, Martin LW, Robinson JG, Hlatky MA. Insulin resistance and risk of cardiovascular disease in postmenopausal women: A cohort study from the Women's Health Initiative. *Circ Cardiovasc Qual Outcomes* 2015;8:309-316.
344. Schmiegelow MD, Hedlin H, Mackey RH, Martin LW, Vitolins MZ, Stefanick ML, Perez MV, Allison M, Hlatky MA. Race and ethnicity, metabolic health and risk of cardiovascular disease in postmenopausal women. *J Am Heart Assoc* 2015;4(5):e001695.

Mark Andrew Hlatky, MD/Page 50

345. Desai M, Joyce V, Bendavid E, Olshen RA, Hlatky M, Chow A, Holodniy M, Barnett P, Owens DK. Risk of cardiovascular events associated with current exposure to HIV antiretroviral therapies in a US Veteran population. *Clin Infect Dis* 2015;61:445-452.
346. Mackey RH, Kuller LH, Deane KD, Walitt BT, Chang YF, Holers VM, Robinson WH, Tracy RP, Hlatky MA, Eaton C, Liu S, Freiberg MS, Talabi MB, Schelbert EB, Moreland LW. Rheumatoid arthritis, anti-CCP positivity, and cardiovascular disease risk in the Women's Health Initiative. *Arthritis Rheumatol* 2015;67:2311-2322.
347. Woo CY, Strandberg EJ, Schmiegelow MD, Pitt AL, Hlatky MA, Owens DK, Goldhaber-Fiebert JD. Cost-effectiveness of adding cardiac resynchronization therapy to an implantable cardioverter-defibrillator among patients with mild heart failure. *Ann Intern Med* 2015;163:417-426.
348. Pontone G, Patel MR, Hlatky MA, Chiswell K, Andreini D, Norgaard BL, Byrne RA, Curzen N, Purcell I, Gutberlet M, Rioufol G, Hink U, Schuchlenz HW, Feuchtner G, Gilard M, De Bruyne B, Rogers C, Douglas PS. Rationale and design of the PLATFORM (Prospective Longitudinal Trial of FFRct: Outcome and Resource IMpacts) study. *Am Heart J* 2015;170:438-446.
349. Shreibati JB, Hlatky MA. Fiscal fitness? Exercise capacity and health care costs. *J Am Coll Cardiol* 2015;66:1886-1887.
350. Hlatky MA, De Bruyne B, Pontone G, Patel MR, Norgaard BL, Byrne RA, Curzen N, Purcell I, Gutberlet M, Rioufol G, Hink U, Schuchlenz HW, Feuchtner G, Gilard M, Andreini D, Jensen JM, Hadamitzky M, Wilk A, Wang F, Rogers C, Douglas PS. Quality of life and economic outcomes of assessing fractional flow reserve with computed tomography angiography: The PLATFORM study. *J Am Coll Cardiol* 2015;66:2315-2323.
351. Schjerning Olsen AM, Lindhardsen J, Gislason GH, McGettigan P, Hlatky MA, Fosbol E, Køber L, Torp-Pedersen C, Lamberts M. Impact of proton pump inhibitor treatment on gastrointestinal bleeding associated with non-steroidal anti-inflammatory drug use among post-myocardial infarction patients taking antithrombotics: nationwide study. *BMJ* 2015;351:h5096.
352. Douglas PS, Pontone G, Hlatky MA, Patel MR, Norgaard BL, Byrne RA, Curzen N, Purcell I, Gutberlet M, Rioufol G, Hink U, Schuchlenz HW, Feuchtner G, Gilard M, Andreini D, Jensen JM, Hadamitzky M, Chiswell K, Cyr D, Wilk A, Wang F, Rogers C, De Bruyne B. Clinical outcomes of fractional flow reserve by computed tomographic angiography-guided diagnostic strategies vs. usual care in patients with suspected coronary artery disease: the prospective longitudinal trial of FFRct: outcome and resource impacts study. *Eur Heart J* 2015;36:3359-3367.
353. Jørgensen ME, Hlatky MA, Køber L, Sanders RD, Torp-Pedersen C, Gislason GH, Jensen PF, Andersson C. Beta blocker associated risks in patients with uncomplicated hypertension undergoing noncardiac surgery. *JAMA Intern Med* 2015;175:1923-1931.
354. Salfati E, Nandkeolyar S, Fortmann SP, Sidney S, Hlatky MA, Quertermous T, Go AS, Iribarren C, Herrington DM, Goldstein BA, Assimes TL. Susceptibility loci for clinical CAD and subclinical coronary atherosclerosis throughout the life-course. *Circ Cardiovasc Genet* 2015;8:803-811.

Mark Andrew Hlatky, MD/Page 51

355. Iribarren C, Chandra M, Rana JS, Hlatky MA, Fortmann SP, Quertermous T, Go AS. Galectin-3 and incident heart failure among patients with pre-existing coronary artery disease: The ADVANCE study. *Clin Trials Regul Sci Cardiol* 2015;5:1-7.
356. Singh A, Schaff HV, Brooks MM, Hlatky MA, Wisniewski SR, Frye RL, Sako EY. On-pump versus off-pump coronary artery bypass graft surgery among patients with type 2 diabetes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial . *Eur J Cardiothorac Surg* 2016;49:406-416.
357. Hlatky MA, Shaw L, Women in cardiology: Very few, different work, different pay. *J Am Coll Cardiol* 2016;67:542-544.
358. Chang TI, Montez-Rath ME, Tsai TT, Hlatky MA, Winkelmayr WC. Drug-eluting stents versus bare-metal stents during PCI in patients with end-stage renal disease on dialysis. *J Am Coll Cardiol* 2016;67:1459-1469.
359. Halperin JL, Levine GN, Al-Khatib SM, Birtcher KK, Bozkurt B, Brindis RG, Cigarroa JE, Curtis LH, Fleisher LA, Gentile F, Gidding S, Hlatky MA, Ikonomidis J, Joglar J, Pressler SJ, Wijeyesundera DN. Further evolution of the ACC/AHA clinical practice guideline recommendation classification system: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation* 2016;133:1426-1428. (Published simultaneously in *J Am Coll Cardiol* 2016;67:1572-1574.)
360. Numé AK, Gislason G, Christiansen CB, Zahir D, Hlatky MA, Torp-Pedersen C, Ruwald MH. Syncope and motor vehicle crash risk: A Danish nationwide study. *JAMA Intern Med* 2016;176:503-510.
361. Rodriguez F, Stefanick ML, Greenland P, Soliman EZ, Manson JE, Parikh N, Martin LW, Larson JC, Hlatky M, Nassir R, Cene C, Rodriguez B, Albert C, Perez MV. Racial and ethnic differences in atrial fibrillation risk factors and predictors in women: Findings from the Women's Health Initiative. *Am Heart J* 2016;176:70-77.
362. Anker SD, Schroeder S, Atar D, Bax JJ, Ceconi C, Cowie MR, Crisp A, Dominjon F, Ford I, Ghofrani A, Gropper S, Hindricks G, Hlatky MA, Holcomb R, Honarpour N, Jukema JW, Kim AM, Kunz M, Lefkowitz M, Le Floch C, Landmesser U, McDonagh TA, McMurray JJ, Merkely B, Packer M, Prasad K, Revkin J, Rosano G, Somaratne R, Stough WG, Voors AA, Ruschitzka F. Traditional and new composite endpoints in heart failure clinical trials: Facilitating comprehensive efficacy assessments and improving trial efficiency. *Eur J Heart Fail* 2016;18:482-489.
363. Azarbal F, Stefanick ML, Assimes TL, Manson JE, Bea JW, Li W, Hlatky MA, Larson JC, LeBlanc ES, Albert CM, Nassir R, Martin LW, Perez MV. Lean body mass and risk of incident atrial fibrillation in post-menopausal women. *Eur Heart J* 2016;37:1606-1613.
364. Iribarren C, Chandra M, Rana JS, Hlatky MA, Fortmann SP, Quertermous T, Go AS. High-sensitivity cardiac troponin I and incident coronary heart disease among asymptomatic older adults. *Heart* 2016;102:1177-1182.

Mark Andrew Hlatky, MD/Page 52

365. Douglas PS, De Bruyne B, Pontone G, Patel MR, Norgaard BL, Byrne RA, Curzen N, Purcell I, Gutberlet M, Rioufol G, Hink U, Schuchlenz HW, Feuchtner G, Gilard M, Andreini D, Jensen JM, Hadamitzky M, Chiswell K, Cyr D, Wilk A, Wang F, Rogers C, Hlatky MA. One-year outcomes of FFR_{CT}-guided care in patients with suspected coronary artery disease: PLATFORM study. *J Am Coll Cardiol* 2016;68:435-445.
366. Hlatky MA. Considering cost-effectiveness in cardiology clinical guidelines: Progress and prospects. *Value Health* 2016;19:516-519.
367. Ermakov S, Azarbal F, Stefanick ML, LaMonte MJ, Li W, Tharp KM, Martin LW, Nassir R, Salmoirago-Blotcher E, Albert CM, Manson JE, Assimes TL, Hlatky MA, Larson JC, Perez MV. The associations of leptin, adiponectin and resistin with incident atrial fibrillation in women. *Heart* 2016;102:1354-1362.
368. Freeman JV, Hutton DW, Barnes GD, Zhu RP, Owens DK, Garber AM, Go AS, Hlatky MA, Heidenreich PA, Wang PJ, Al-Ahmad A, Turakhia MP. Cost-effectiveness of percutaneous closure of the left atrial appendage in atrial fibrillation based on results from PROTECT AF vs. PREVAIL. *Circ Arrhythm Electrophysiol* 2016;9(6):e003407.
369. Ben-Yehuda O, Kazi DS, Bonafede M, Wade SW, Machacz SF, Stephens LA, Hlatky MA, Hernandez JB. Angina and associated healthcare costs following percutaneous coronary intervention: A real-world analysis from a multi-payor database. *Catheter Cardiovasc Interv* 2016;88:1017-1024.
370. Ikeno F, Brooks MM, Nakagawa K, Kim MK, Kaneda H, Mitsutake Y, Vlachos HA, Schwartz L, Frye RL, Kelsey SF, Waseda K, Hlatky MA. SYNTAX score and long-term outcomes: The BARI 2D trial. *J Am Coll Cardiol* 2017;69:395-403.
371. Shreibati JB, Goldhaber-Fiebert JD, Banerjee D, Owens DK, Hlatky MA. Cost-effectiveness of left ventricular assist devices in ambulatory patients with advanced heart failure. *JACC Heart Fail* 2017;5:110-119.
372. Colleran R, Douglas PS, Hadamitzky M, Gutberlet M, Lehmkuhl L, Foldyna B, Woinke M, Hink U, Nadjiri J, Wilk A, Wang F, Pontone G, Hlatky MA, Rogers C, Byrne RA. An FFR_{CT} diagnostic strategy versus usual care in patients with suspected coronary artery disease planned for invasive coronary angiography at German sites: One-year results of a subgroup analysis of the PLATFORM (Prospective Longitudinal Trial of FFR_{CT}: Outcome and resource IMPacts) study. *Open Heart* 2017;4:e000526.
373. Jørgensen ME, Andersson C, Nørgaard BL, Abdulla J, Shreibati JB, Torp-Pedersen C, Gislason GH, Shaw RE, Hlatky MA. Functional testing or coronary computed tomography angiography in patients with stable coronary artery disease. *J Am Coll Cardiol* 2017;69:1761-1770.

Mark Andrew Hlatky, MD/Page 53

374. Numé AK, Kragholm K, Carlson N, Kristensen SL, Bøggild H, Hlatky MA, Gislason G, Torp-Pedersen C, Ruwald MH. Syncope and its impact on occupational accidents and employment: A Danish nationwide retrospective cohort study. *Circ Cardiovasc Qual Outcomes* 2017;10(4):pii:e003202.
375. Hlatky MA, Januzzi JL. Manuscripts based on datasets shared by clinical research studies. *J Am Coll Cardiol* 2017;69:1983-1985.
376. Hlatky MA. Are novel oral anticoagulants worth their cost? *JAMA Cardiol* 2017;2:534-535.
377. Jørgensen ME, Sanders RD, Køber L, Mehta K, Torp-Pedersen C, Hlatky MA, Pallisgaard JL, Shaw RE, Gislason GH, Jensen PF, Andersson C. Beta-blocker subtype and risks of perioperative adverse events following non-cardiac surgery: A nationwide cohort study. *Eur Heart J* 2017;38:2421-2428.
378. Rao G, Lopez-Jimenez F, Boyd J, D'Amico F, Durant NH, Hlatky MA, Howard G, Kirley K, Masi C, Powell-Wiley TM, Solomonides AE, West CP, Wessel J. Methodological standards for meta-analyses and qualitative systematic reviews of cardiac prevention and treatment studies. A Scientific Statement from the American Heart Association. *Circulation* 2017;136:e172-e194.
379. Lindholm D, James S, Lagerquist B, Hlatky MA, Varenhorst C. New method for assessing the effect of driving distance to hospital care: Using OpenStreetMap routing in cardiovascular research. *Circ Cardiovasc Qual Outcomes* 2017;10:e003850.
380. Mark DB, Richman I, Hlatky MA. Proprotein convertase subtilisin/kexin type 9 inhibitor therapy—Breakthrough in low-density lipoprotein cholesterol lowering, breakdown in value. *JAMA Cardiol* 2017;2:1066-1068.
381. Hlatky MA, Kazi DS. PCSK9 inhibitors: Economics and policy. *J Am Coll Cardiol* 2017;70:2677-2687.
382. Katus H, Ziegler A, Ekinici O, Giannitsis E, Stough WG, Achenbach S, Blankenberg S, Brueckmann M, Collinson P, Comaniciu D, Crea F, Dinh W, Ducrocq G, Flachskampf F, Fox KAA, Friedrich MG, Hebert K, Himmelmann A, Hlatky M, Lautsch D, Lindahl B, Lindholm D, Mills NL, Minotti G, Möckel M, Omland T, Semjonow V. Early diagnosis of acute coronary syndrome. *Eur Heart J* 2017;38:3049-3055.
383. Fearon WF, Nishi T, De Bruyne B, Boothroyd DB, Barbato E, Tonino P, Jüni P, Pijls NHJ, Hlatky MA. Clinical outcomes and cost-effectiveness of fractional flow reserve-guided percutaneous coronary intervention in patients with stable coronary artery disease. Three-year follow-up of the FAME 2 trial. *Circulation* 2018;137:480-487.
384. Sehested TSG, Gerds TA, Fosbøl EL, Hansen PW, Charlot MG, Carlson N, Hlatky MA, Torp-Pedersen C, Gislason GH. Long-term use of proton pump inhibitors, dose-response relationship, and associated risk of ischemic stroke and myocardial infarction. *J Intern Med* 2018;283:268-281.

Mark Andrew Hlatky, MD/Page 54

385. Head SJ, Milojevic M, Daemen J, Ahn JM, Boersma E, Christiansen EH, Domanski MJ, Farkouh ME, Flather M, Fuster V, Hlatky MA, Holm NR, Hueb WA, Kamalesh M, Kim YH, Mäkikallio T, Mohr FW, Papageorgiou G, Park SJ, Rodriguez AE, Sabik JF, Stables RH, Stone GW, Serruys PW, Kappetein AP. Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: A pooled analysis of individual patient-data. *Lancet* 2018;391:939-948.
386. Shreibati JB, Manson JE, Margolis KL, Chlebowski RT, Stefanick ML, Hlatky MA. Impact of hormone therapy on Medicare spending in the Women's Health Initiative randomized clinical trials. *Am Heart J* 2018;198:108-114.
387. Van Nuys KE, Xie Z, Tysinger B, Hlatky MA, Goldman DP. Innovation in heart failure treatment: Life expectancy, disability, and health disparities. *JACC Heart Fail* 2018;6:401-409.
388. Hlatky MA. A mentor's perspective on using shared research data. *J Am Coll Cardiol* 2018;71:2077-2078.
389. Pallisgaard JL, Brooks MM, Chaitman B, Boothroyd DB, Perez M, Hlatky MA. Thiazolidinediones and risk of atrial fibrillation among patients with diabetes mellitus and coronary disease. *Am J Med* 2018;131:805-812.
390. Go AS, Hlatky MA, Liu TI, Fan D, Garcia EA, Sung SH, Solomon MD. Contemporary burden and correlates of symptomatic paroxysmal supraventricular tachycardia. *J Am Heart Assoc* 2018;7:e008759. DOI: 10.1161/JAHA.118.008759.
391. Head SJ, Milojevic M, Daemen J, Ahn JM, Boersma E, Christiansen EH, Domanski MJ, Farkouh ME, Flather M, Fuster V, Hlatky MA, Holm NR, Hueb WA, Kamalesh M, Kim YH, Mäkikallio T, Mohr FW, Papageorgiou G, Park SJ, Rodriguez AE, Sabik JF, Stables RH, Stone GW, Serruys PW, Kappetein AP. Stroke rates following surgical versus percutaneous coronary revascularization. *J Am Coll Cardiol* 2018;72:386-398.
392. Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, Deal BJ, Dickfeld T, Field ME, Fonarow GC, Gillis AM, Granger CB, Hammill SC, Hlatky MA, Joglar JA, Kay GN, Matlock DD, Myerburg RJ, Page RL. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. *J Am Coll Cardiol* 2018;72:1677-1749. (Published simultaneously in *Circulation* 2018;138:e210-e271 and *Heart Rhythm* 2018:e190-e252.)
393. Rezende PC, Everett BM, Brooks MM, Vlachos H, Orchard TJ, Frye RL, Bhatt DL, Hlatky MA. Hypoglycemia and elevated troponin in patients with diabetes and coronary artery disease. *J Am Coll Cardiol* 2018;72:1778-1786.

Mark Andrew Hlatky, MD/Page 55

394. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith Jr SC, Sperling L, Virani SS, Yeboah J. 2018 AHA/ACC/AACVPR/ AAPA/ABC/ACPM/ADA/AGS/APhA/ ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. *J Am Coll Cardiol* 2018 [Epub ahead of print] doi: <https://doi.org/10.1016/j.jacc.2018.11.003>. (Published simultaneously in *Circulation* 2018).
395. Reynolds MR, Hlatky MA. Replace or repair? The economics of mitral valve surgery. *Circ Cardiovasc Qual Outcomes* 2018;11:e005093.
396. Sehested TSG, Bjerre J, Ku S, Chang A, Jahansouz A, Owens DK, Hlatky MA, Goldhaber-Fiebert JD. Cost-effectiveness of canakinumab for prevention of recurrent cardiovascular events. *JAMA Cardiol* 2019;4:128-135.
397. Levine GN, O’Gara PT, Beckman JA, Al-Khatib SM, Birtcher KK, Cigarroa JE, de las Fuentes L, Deswal A, Fleisher LA, Gentile F, Goldberger ZD, Hlatky MA, Ikonomidis J, Joglar JA, Piano MR, Wiyeysondera DN. Recent innovations, modifications, and evolution of ACC/AHA clinical practice guidelines: An update for our constituencies. A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol* 2019;73:1990-1998. (Published simultaneously in *Circulation* 2019;139:e879-e886.)
398. Han X, Ghaemi MS, Ando K, Peterson LS, Ganio EA, Tsai AS, Gaudilliere DK, Stelzer IA, Einhaus J, Bertrand B, Stanley N, Culos A, Taneda A, Hedou J, Tsai ES, Fallahzadeh R, Wong RJ, Judy AE, Winn VD, Druzin ML, Blumenfeld YJ, Hlatky MA, Quaintance C, Gibbs RS, Carvalho B, Shaw GM, Stevenson DK, Angst MS, Aghaeepour N, Gaudilliere B. Differential dynamics of the maternal immune system in healthy pregnancy and preeclampsia. *Front Immunol* 2019;10:1305. doi: 10.3389/fimmu.2019.01305.
399. Hlatky MA. A pound of prevention? Assessing the value of PCSK9 inhibitors. *Ann Intern Med* [Epub ahead of print].
400. Bonde AN, Blanche P, Staerk L, Gerds TA, Gundlund A, Gislason G, Torp-Pedersen C, Lip GYH, Hlatky MA, Olesen JB. Oral anticoagulation among atrial fibrillation patients with anemia: An observational cohort study. *Eur Heart J* [Epub ahead of print].
401. Sehested TSG, Carlson N, Hansen PW, Gerds TA, Charlot MG, Torp-Pedersen C, Køber L, Gislason GH, Hlatky MA, Føsbøl EL. Reduced risk of gastrointestinal bleeding associated with proton pump inhibitor therapy in patients treated with dual antiplatelet therapy after myocardial infarction. *Eur Heart J* [Epub ahead of print].

MANUSCRIPTS

1. Hansen PW, Aghaeepour N, Gerds TA, Sehested TSG, Clemmensen L, Fosbøl EL, Torp-Pedersen C, Hlatky MA, Gislason GH, Andersson C. Explorative search for NOAC-drug interactions – A nationwide cohort study (submitted).
2. Bonde AN, Bjerre J, Proietti M, Lip GYH, Gislason G, Hlatky M. Men who live alone have poor anticoagulation control: An analysis of atrial fibrillation patients on vitamin K antagonist from Danish registries (submitted).
3. Freeman JV, Tabada GH, Reynolds K, Sung SH, Singer DE, Wang PJ, Liu TI, Gupta N, Hlatky MA, Go AS. Long-term risk of adverse outcomes after atrial fibrillation ablation compared with antiarrhythmic medications: A propensity-matched cohort study (submitted).
4. Mahmoudi M, Nicholas Z, Nuttall J, Bresser M, Maishman T, Berry C, Hlatky MA, Douglas P, Rajani R, Fox K, Curzen N. Fractional flow reserve derived from computed tomography coronary angiography in the assessment and management of stable chest pain: Rationale and design of the FORECAST trial (submitted).
5. Sarnak MJ, Amann K, Bangalore S, Cavalcante JL, Charytan DM, Craig JC, Gill JS, Hlatky MA, Jardine AG, Landmesser U, Newby LK, Herzog CA, Cheung M, Wheeler DC, Winkelmayr WC, Marwick TH. Chronic kidney disease and coronary artery disease: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference (submitted).

Mark Andrew Hlatky, MD/Page 57

SPECIAL ISSUES EDITED

1. Comparative effectiveness research in heart failure. *Heart Fail Clin*, January 2013 (Volume 9, Number 1).
2. Health policy and cardiac electrophysiology. *J Interv Card Electrophysiol*, March 2013 (Volume 36, Number 2).

TECHNICAL REPORTS

1. Heidenreich PA, McDonald KM, Hastie T, Fadel B, Hagan V, Lee BK, Hlatky MA. An evaluation of beta-blockers, calcium antagonists, nitrates, and alternative therapies for stable angina. (Evidence Report/Technology Assessment No. 10 [Contract 290-97-00131] to the University of California San Francisco-Stanford Evidence-based Practice Center). AHRQ Publication No. 00-E003. Rockville, MD: Agency for Healthcare Research and Quality. November 1999.
2. Heidenreich PA, Go A, Melsop KA, Alloggiamento T, McDonald KM, Hagan V, Hastie T, Hlatky MA. Prediction of risk for patients with unstable angina. (Evidence Report/Technology Assessment No. 31 [Contract 290-97-00131] to the University of California San Francisco-Stanford Evidence-based Practice Center). AHRQ Publication No. 01-E001. Rockville, MD: Agency for Healthcare Research and Quality. December 2000.
3. Sanders GD, Hlatky MA, Owens DK. Special Report: Cost-effectiveness of implantable cardioverter defibrillators in a MADIT-II population. Blue Cross Blue Shield Association. Technology Evaluation Center. Assessment Program, Volume 19, Number 5, April 2004.
4. Bravata DM, McDonald KM, Gienger AL, Sundaram V, Perez MV, Varghese R, Kapoor JR, Ardehali R, McKinnon MC, Stave CD, Owens DK, Hlatky MA. Comparative effectiveness of percutaneous coronary interventions and coronary artery bypass grafting for coronary artery disease. Comparative Effectiveness Review No. 9. (Prepared by Stanford-UCSF Evidence-based Practice Center under Contract #290-02-0017.) Rockville, MD: Agency for Healthcare Research and Quality. October 2007.
5. Institute of Medicine (Writing Committee: Wenger NK, Boden WE, Carabello BA, Carney RM, Cerqueira MD, Criqui MH, Epstein AE, Froelicher ES, Gibbons GH, Hlatky MA, Jacobs AK, Kuehl KK, Miller TD, Stevenson LW). Cardiovascular disability: Updating the Social Security listings. Washington, DC: The National Academies Press, 2010.

BOOK CHAPTERS

1. Lee KL, Harrell FE Jr, Califf RM, Pryor DB, Hlatky MA, Rosati RA. Secondary prevention trials in post-myocardial infarction patients: Methodologic issues. In: Kulbertus HE, Wellens HJJ, eds. The first year after a myocardial infarction. Mount Kisco NY: Futura Publishing Company, 1983: 407-19.
2. Hlatky MA, Hulley SB. Cardiac risk factor modification. In: Dornbrand L, Hoole AJ, Fletcher RH, Pickard CG Jr, eds. Manual of clinical problems in adult ambulatory care. Boston: Little, Brown and Co, 1985:514-17.
3. Kottke T, Hlatky MA, Hindman MC, Califf RM. Rehabilitation after myocardial infarction. In: Dornbrand L, Hoole AJ, Fletcher RH, Pickard CG Jr, eds. Manual of clinical problems in adult ambulatory care. Boston: Little, Brown and Co, 1985:132-35.
4. Hlatky MA, Mark DB. Overview of test diagnostic assessment. In: Califf RM, Mark DB, Wagner GS, eds. Acute coronary care in the thrombolytic era. Chicago: Year Book Medical Publishers, 1988:91-99.
5. McIntyre RW, Hlatky MA, Reves JG. General anesthesia in the acute myocardial infarction patient. In: Califf RM, Mark DB, Wagner GS, eds. Acute coronary care in the thrombolytic era. Chicago: Year Book Medical Publishers, 1988:364-75.
6. Mark DB, Hlatky MA, Pryor DB. The exercise treadmill test in patients recovering from an acute myocardial infarction. In: Califf RM, Mark DB, Wagner GS, eds. Acute coronary care in the thrombolytic era. Chicago: Year Book Medical Publishers, 1988:573-91.
7. Pryor DB, Harrell FE Jr, Rankin JS, Lee KL, Muhlbaier LH, Hlatky MA, Mark DB, Oldham HN, Reves JG, Califf RM. Trends in the presentation, management, and survival of patients with coronary artery disease: The Duke database for cardiovascular disease. In: Higgins MW, Luepker RV, eds. Trends in coronary heart disease mortality. The influence of medical care. New York: Oxford University Press, 1988:76-87.
8. Califf RM, Ohman EM, Frid DJ, Fortin DF, Mark DB, Hlatky MA, Herndon JE, Bengston JR. Restenosis: The clinical issues. In: Topol EJ, ed. Textbook of interventional cardiology. Philadelphia: W. B. Saunders, 1990:363-394.
9. Hlatky MA, Califf RM, Harrell FE Jr, Lee KL, Mark DB, Muhlbaier LH, Pryor DB. Clinical judgment and therapeutic decision making. In: Knoebel SB, Dack S, eds. An era in cardiovascular medicine. New York: Elsevier Science Publishing, 1991:303-315. (Reprint of J Am Coll Cardiol 1990; 15:1-14.)
10. Hlatky MA. Acute myocardial infarction - present and future costs and benefits associated with the rapid identification and treatment. In: LaRosa JH, Horan MJ, Passamani ER, editors. Proceedings of the National Heart, Lung, and Blood Institute symposium on rapid identification and treatment of acute myocardial infarction 1990, Oct:10-12; Washington, DC. Washington, DC: National Heart, Lung, and Blood Institute, 1991:111-14.

Mark Andrew Hlatky, MD/Page 60

11. Hlatky MA, Mark DB. Angina Pectoris. In: Dornbrand L, Hoole AJ, Pickard CG Jr, eds. Manual of clinical problems in adult ambulatory care. 2nd ed. Boston: Little, Brown and Co, 1992:126-133.
12. Kottke TE, Hlatky MA. Rehabilitation after myocardial infarction. In: Dornbrand L, Hoole AJ, Pickard CG Jr, eds. Manual of clinical problems in adult ambulatory care. 2nd ed. Boston: Little, Brown and Co, 1992:139-142.
13. Hlatky MA, Hulley SB. Cardiac risk factor modification. In: Dornbrand L, Hoole AJ, Pickard CG Jr, eds. Manual of clinical problems in adult ambulatory care. 2nd ed. Boston: Little, Brown and Co, 1992:616-619.
14. Hlatky MA. Combining data from different studies. In: Grady ML, Schwartz HA, eds. Medical effectiveness research data methods. Rockville, MD: Agency for Health Care Policy and Research. Publication No. 92-0056; 1992:33-36
15. Hlatky MA. Clinical decision making. In: Roubin GS, Califf RM, O'Neill WW, Phillips HR III, Stack RS, eds. Interventional cardiovascular medicine: Principles and practice. New York: Churchill Livingstone, 1994;197-201.
16. Hlatky MA. Observational databases. In: Califf RM, Mark DB, Wagner GS, eds. Acute coronary care. 2nd ed. St. Louis: Mosby, 1995;145-147.
17. Sanders GD, Harris RA, Hlatky MA, Owens DK. Prevention of sudden cardiac death: a probabilistic model for decision support. In: Proceedings of the Nineteenth Annual Symposium on Computer Applications in Medical Care; October 28 - November 1, 1995;1:258-262.
18. Hlatky MA, Mark DB, Stettin GD. Angina pectoris. In: Dornbrand L, Hoole AJ, Fletcher RH. Manual of clinical problems in adult ambulatory care. 3rd ed. Philadelphia: Lippincott-Raven, 1997;133-142.
19. Hlatky MA, Hulley SB. Cardiac risk factor modification. In: Dornbrand L, Hoole AJ, Fletcher RH. Manual of clinical problems in adult ambulatory care. 3rd ed. Philadelphia: Lippincott-Raven, 1997;658-661.
20. Hlatky MA. Palpitations. In: Goldman L, Braunwald E, eds. Primary cardiology. Philadelphia: W.B. Saunders, 1998;122-128.
21. Hlatky MA. Understanding concepts related to health economics. In: Yusuf S, Cairns JA, Camm AJ, Fallen EL, Gersh BJ, eds. Evidence based cardiology. London: BMJ Books, 1998;76-91.
22. Cheng CHF, Sanders GD, McDonald KM, Heidenreich PA, Hlatky MA, Owens DK. Design of a modular, extensible decision support system for arrhythmia therapy. Proceedings of the AMIA Annual Fall Symposium, 1998:693-697.

Mark Andrew Hlatky, MD/Page 61

23. Hlatky MA. The evolution of the cost of coronary bypass surgery. In: Pintor AP, ed., Proceedings of the symposium, "Costs and risks of heart surgery." Torino, Italy: Fondazione Arturo Pinna Pintor, 2000:23-26.
24. Hlatky MA, Mark DB. Economics and cardiovascular disease. In: Braunwald E, Zipes DP, Libby P, eds. Heart disease: A textbook of cardiovascular medicine, 6th ed. Philadelphia: WB Saunders, 2001:19-26.
25. McClellan MB, Every N, Garber AM, Heidenreich P, Hlatky M, Kessler DP, Newhouse J, Saynina O. Technological change in heart attack care in the United States. In: McClellan MB, Kessler DP, eds. Technological change in health care. Ann Arbor: The University of Michigan Press, 2002:21-54.
26. Hlatky MA. Understanding concepts related to health economics. In: Yusuf S, Cairns JA, Camm AJ, Fallen EL, Gersh BJ, eds. Evidence based cardiology, 2nd ed. London: BMJ Books, 2003;46-55.
27. Hlatky MA. Approach to the patient with palpitations. In: Braunwald E, Goldman L, eds. Primary cardiology, 2nd ed. Philadelphia: Saunders, 2003:129-136.
28. Hlatky MA. Economic comparisons of coronary angioplasty and coronary bypass surgery. In: Weintraub WS, ed. Contemporary cardiology: Cardiovascular health care economics. Totowa, NJ: Humana Press, 2003;223-232.
29. Hlatky MA, Mark DB. Economics and cardiovascular disease. In: Zipes DP, Libby P, Bonow RO, Braunwald E, eds. Heart disease: A textbook of cardiovascular medicine, 7th ed. Philadelphia: WB Saunders, 2005; 20-26.
30. Hlatky MA. Use of statistics in cardiovascular clinical research. In: Lewis RP, O'Gara PT, Hirsch G, eds. Adult clinical cardiology self-assessment program. 6th ed. Bethesda: American College of Cardiology, 2005;5.1-5.5.
31. Kazi DS, Hlatky MA. The cost-effectiveness of cardiac resynchronization therapy. In: Abraham WT, Baliga RR, eds. Cardiac resynchronization therapy in heart failure. Philadelphia: Wolters Kluwer/Lipincott Williams & Wilkins, 2009; 137-143.
32. Hlatky MA. Understanding concepts related to health economics. In: Yusuf S, Cairns JA, Camm AJ, Fallen EL, Gersh BJ, eds. Evidence based cardiology, 3rd ed. London: BMJ Books, 2010;38-46.

Mark Andrew Hlatky, MD/Page 62

OTHER PUBLICATIONS

1. Harrell FE Jr, Lee KL, McKinnis RA, Hlatky MA, Mark D, Califf RM, Pryor DB. Analysis of risk factors for sudden death after acute myocardial infarction. *Am J Cardiol* 1985;55:621-622 (letter).
2. Hlatky MA. Reply: Routine electrocardiograms on admission. *Ann Intern Med* 1986;104:444-445 (letter).
3. Hlatky MA. Intracoronary streptokinase versus coronary angioplasty for acute myocardial infarction. *N Engl J Med* 1986;315:1093-1094 (letter).
4. Moorman JR, Hlatky MA. Should electrocardiograms be performed routinely at hospital admission? *Cardiol Board Rev* 1986;3(4):41-44.
5. Califf RM, Papanicolaou MN, McCants CB, Hlatky MA, Pryor DB. Prognosis in angiographically normal or near-normal coronary arteries. *Cardiol Board Rev* 1987;4(7):21-25.
6. Mark DB, Hlatky MA, Pryor DB. Coronary obstructions: Location with exercise electrocardiography. *Cardiol Board Rev* 1987;4(7):90-99.
7. Mark DB, Hlatky MA, Harrell FE Jr, Lee KL, Califf RM, Pryor DB. Reply: Treadmill score for predicting prognosis in coronary artery disease. *Ann Intern Med* 1987;107:595-596 (letter).
8. Mark DB, Hlatky MA, Pryor DB. Using the exercise treadmill test to predict outcome in coronary artery disease. *Cardiol Board Rev* 1988;5(2):163-171.
9. Bashore TM, Davidson CJ, Mark DB, Kisslo K, Hlatky MA, Skelton TN. Iopamidol use in the cardiac catheterization laboratory: A retrospective analysis of 3313 patients. *Cardio* 1988;5 (3, Part 2):6-10.
10. Hlatky MA. Reply: The origin of the specious. *Am J Cardiol* 1988;62:177 (letter).
11. Hlatky MA. Recent changes in management of acute myocardial infarction. *Cardiol Board Rev* 1988;5(12):58-67.
12. Mark DB, Hlatky MA, Pryor DB. Silent ischemia on the treadmill: What does it mean? *Cardio* 1989;6(2):99-104.
13. Schwab SJ, Hlatky MA, Pieper KS, Davidson CJ, Morris KG, Bashore TM, Skelton TN. Reply: Contrast nephrotoxicity, *N Engl J Med* 1989;321:397 (letter).
14. Bengtson JR, Bashore TM, Lee JC, Hlatky MA. Outpatient cardiac catheterization. *Cardio* 1990; 7(1):43-46.
15. Hlatky MA. Commentary on "Rt-PA plus heparin or low dose aspirin for acute myocardial infarction?" *ACP J Club* 1991 Mar/Apr:34 (*Ann Intern Med*, Vol. 114, Suppl 2).

Mark Andrew Hlatky, MD/Page 63

16. Hlatky MA. Commentary on "Streptokinase for acute myocardial infarction: A meta-analysis." ACP J Club 1991 Mar/Apr:35 (Ann Intern Med, Vol. 114, Suppl 2).
17. Hlatky MA. Commentary on "Adjuncts to thrombolysis after myocardial infarction: A review." ACP J Club 1991 Nov/Dec:69 (Ann Intern Med, Vol. 115, Suppl 3).
18. Hlatky MA. Commentary on "Post-infarction angina with and without electrocardiographic signs." ACP J Club 1992 Mar/Apr:57 (Ann Intern Med, Vol. 116, Suppl 2).
19. Hlatky MA. Commentary on "Intravenous magnesium for acute myocardial infarction: A meta-analysis." ACP J Club 1992 May/Jun:68 (Ann Intern Med, Vol. 116, Suppl 3).
20. Hlatky MA. Commentary on "Antithrombotic and fibrinolytic regimens for acute myocardial infarction." ACP J Club 1992 Jul/Aug:3 (Ann Intern Med, Vol 117, Suppl 1).
21. Hlatky MA. Reply: Intravenous magnesium for acute myocardial infarction. ACP J Club 1992 Sep/Oct:62 (Ann Intern Med, Vol 117, Suppl 2) (letter).
22. Hlatky MA. Commentary on "Late angioplasty after thrombolysis for myocardial infarction." ACP J Club 1993 May/Jun:75 (Ann Intern Med, Vol 118, Suppl 3).
23. Hlatky MA. Commentary on "Mechanical heart valves and bioprostheses after 11 years." ACP J Club 1993 Sep/Oct:41 (Ann Intern Med, Vol 119, Suppl 2).
24. Omoigui N, Hlatky M. Are the major "historic" randomized trials of coronary artery bypass surgery still relevant to decision making today? ACC Curr J Rev 1994 May/Jun: 56-59.
25. Hlatky MA. Commentary on "Immediate angioplasty was better than streptokinase in acute MI." ACP J Club 1994 Sep/Oct:42 (Ann Intern Med, Vol 121, Suppl 2).
26. Hlatky MA. Commentary on "Early coronary bypass surgery lowers mortality." ACP J Club 1995 Mar/Apr:29 (Ann Intern Med, Vol 122, Suppl 2).
27. Hlatky MA. Commentary on "Captopril but not mononitrate or intravenous magnesium reduced short-term mortality after suspected myocardial infarction." ACP J Club 1995 Sep/Oct:44 (Ann Intern Med, Vol. 123, Suppl 2) (Reprinted in Evid Based Med 1995;1:19).
28. Hlatky MA. Reply: Preoperative cardiac evaluation and perioperative monitoring for non-cardiac vascular surgery. JAMA 1995;274:1672 (letter).
29. Hlatky MA. Reply: Job strain and the prevalence and outcome of coronary artery disease. Circulation 1996;94:1141 (letter).
30. Hlatky MA. Commentary 3: Cost-effectiveness issues. 27th Bethesda Conference: Matching the intensity of risk factor management with the hazard for coronary disease events. Abstracts of Clinical Care Guidelines 1997;9(1):17-19.

Mark Andrew Hlatky, MD/Page 64

31. Hlatky MA. Reply: Cost-effectiveness of coronary bypass surgery versus angioplasty. *N Engl J Med* 1997;336:1840-1841 (letter).
32. Hlatky MA. Commentary on "Population-wide educational strategies for serum cholesterol reduction are cost-effective." *Evid Based Cardiovasc Med* 1997;1:82.
33. Hlatky MA. Commentary on "Enoxaparin had lower costs than unfractionated heparin for acute coronary syndrome." *ACP J Club* 1998 Nov-Dec;129:80. (Reprinted in *Evid Based Med* 1998 Nov-Dec;3:193.)
34. Hlatky M, Spertus JA. Practical use of quality of life testing. *ACC Curr J Rev* 1998 Nov/Dec;7(6):90-93.
35. Hlatky MA, Owens DK. Cost-effectiveness of the implantable cardioverter defibrillator. *Card Electrophysiol Rev* 1998;2:319-321.
36. Schwartz JS, Brown WV, Hlatky M, Castelli W. Cardiovascular disease and lipoproteins: Available evidence and remaining questions. Reactor panel and open forum. *Value Health* 1998;1:125-130.
37. Hlatky MA. Commentary on "Cost-effectiveness of early discharge after uncomplicated acute myocardial infarction." *ACP J Club* 2000 Nov-Dec;133:120. (Reprinted in *Evid Based Med* 2000 Nov-Dec;5:190.)
38. Hlatky MA, Owens DK. Cost-effectiveness of the implantable cardioverter defibrillator. *Card Electrophysiol Rev* 2001;5:105-107.
39. Groeneveld PW, Hlatky MA. Commentary on "Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery." *ACP J Club* 2001 Jul-Aug;135:5. (Reprinted in *Evid Based Med* 2001 Jul-Aug;6:114.)
40. Heidenreich PA, Cheng CH, Sanders GD, McDonald KM, Lee BK, Larson MS, Hlatky MA, Owens DK. Radiofrequency ablation for supraventricular tachycardia. *Cardiol Rev* 2001;18(11):8-13.
41. Hlatky MA. Commentary on "Stents had similar clinical outcomes but more repeated revascularization than did bypass surgery in multivessel disease." *ACP J Club* 2001 Nov-Dec;135:89.
42. Hlatky MA, Boothroyd D. Reply: Postmenopausal hormone replacement, body mass index, and quality of life. *JAMA* 2002;287;2210-2211 (letter).
43. Hlatky MA. Commentary on "Prophylactic implantation of a defibrillator in patients with myocardial infarction and a reduced ejection fraction." *ACP J Club* 2002 Nov-Dec;137:81.
44. Hlatky MA, Sanders GD, Owens DK. Cost-effectiveness of the implantable cardioverter defibrillator. *Card Electrophysiol Rev* 2003;7:479-482.

Mark Andrew Hlatky, MD/Page 65

45. Hlatky MA. Closing the gaps between evidence and practice. *SGH Proceedings* 2004;13:6-11.
46. Assimes T, Hlatky MA. Commentary on “Cardiac outcomes occurred more frequently with PCI than CABG or medical therapy in coronary artery disease.” *ACP J Club* 2004 Nov-Dec;141:57.
47. Sanders GD, Hlatky MA, Owens DK. Reply: Cost-effectiveness of ICDs. *N Engl J Med* 2006;354:206-207 (letter).
48. Hlatky M, Sanders G. Commentary on “Multislice computed tomography detected coronary artery disease.” *Evid Based Med* 2006;11:24.
49. Hlatky M, Giacomini J. Commentary on “Same-day discharge after elective percutaneous coronary intervention was non-inferior for safety to staying overnight in hospital.” *ACP J Club* 2007 Sep-Oct;147:35.
50. Hlatky MA, Bravata DM. Commentary on “Rosiglitazone increases risk for MI but does not differ from other drugs for CV death in Type 2 diabetes,” and “Rosiglitazone increased heart failure, but did not differ from metformin plus sulfonylurea for other CV outcomes at interim analysis.” *ACP J Club* 2007 Nov-Dec; 147:66-67. (Reprinted in *Evid Based Med* 2007;12:169-170).
51. Lee KK, Hlatky MA. Commentary on “Reynolds risk score for men predicted cardiovascular events more accurately than traditional risk factors only.” *ACP J Club* 2009;150:JC3-14.
52. Hlatky MA, Bravata DM, McDonald KM, Owens DK. Reply: CABG versus PCI for multivessel coronary artery disease. *Lancet* 2009;373:2200 (letter).
53. Massie B, Cleland J, Hlatky MA, Stevenson L. The role of implantable defibrillators in cardiac resynchronization therapy in heart failure patients. *Med Roundtable Cardiovasc Ed* 2011;2:107-116.
54. Hlatky MA, Boothroyd DB. Reply: Comparative effectiveness of multivessel coronary artery bypass graft surgery and multivessel percutaneous coronary intervention. *Ann Intern Med* 2013;159:435 (letter).
55. Fearon WF, Shilane D, Pijls NH, Boothroyd DB, Tonino PA, Barbato E, Juni P, De Bruyne B, Hlatky MA. Response: Cost-effectiveness of percutaneous coronary intervention in patients with stable coronary artery disease and abnormal fractional flow reserve. *Circulation* 2014;129:e684 (letter).
56. Hlatky M. Reply: A commentary on the SPARC study. *J Am Coll Cardiol* 2014;64:741 (letter).
57. Kazi DS, Owens DK, Hlatky MA. Response: Cost-effectiveness of genotype-guided and dual antiplatelet therapies. *Ann Intern Med* 2014;161:378-379 (letter).

Mark Andrew Hlatky, MD/Page 66

58. Hlatky MA, Andersson C, Chang TI, Kazi D, Solomon MD, Go AS. Reply: Beta-blockers for angina: Time to reassess the specific impact of drug therapy in coronary heart disease patients. *J Am Coll Cardiol* 2014;64: 2712 (letter).
59. Kazi DS, Hlatky MA. Reply: The value of pharmacogenetic testing. *JAMA Intern Med* 2015;175:314-315 (letter).
60. Hlatky MA. ACP J Club Commentary on “Review: In diabetes with multivessel or left main CAD, PCI increases death/MI/stroke combo compared with CABG.” *Ann Intern Med* 2015;162(6): JC8.
61. Desai M, Joyce V, Bendavid E, Olshen RA, Hlatky M, Chow A, Holodniy M, Barnett P, Owens DK. Reply: Incomplete modeling of the effect of antiretroviral therapy on the risk of cardiovascular events. *Clin Infect Dis* 2015;61:1207-1208 (letter).
62. Jørgensen ME, Hlatky MA, Andersson C. Reply: Association of β -blocker treatment with adverse outcomes in hypertensive patients undergoing noncardiac surgery. *JAMA Intern Med* 2016;176:563-564 (letter).
63. Nume AK, Hlatky MA, Ruwald MH. Reply: Syncope while driving in Denmark. *JAMA Intern Med* 2016;176:1230-1231 (letter).
64. Sehested TSG, Hlatky MA, Carlson N, Gislason GH. Reply: Proton-pump inhibitor use and risk of first-time ischemic stroke in the general population. *J Intern Med* 2017 [Epub ahead of print].